Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,2499248,total body clearance,"As a consequence of a declining renal clearance but not nonrenal clearance, the total body clearance of fleroxacin declined with decreasing glomerular filtration rate from 1.41 +/- 0.23 ml/min per kg in subjects with normal renal function to 0.58 +/- 0.13 ml/min per kg in patients with end-stage renal disease (r = 0.84, P less than 0.001).",Pharmacokinetics and metabolism of intravenous and oral fleroxacin in subjects with normal and impaired renal function and in patients on continuous ambulatory peritoneal dialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2499248/),[ml] / [kg·min],1.41,5528,DB04576,Fleroxacin
,2499248,total body clearance,"As a consequence of a declining renal clearance but not nonrenal clearance, the total body clearance of fleroxacin declined with decreasing glomerular filtration rate from 1.41 +/- 0.23 ml/min per kg in subjects with normal renal function to 0.58 +/- 0.13 ml/min per kg in patients with end-stage renal disease (r = 0.84, P less than 0.001).",Pharmacokinetics and metabolism of intravenous and oral fleroxacin in subjects with normal and impaired renal function and in patients on continuous ambulatory peritoneal dialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2499248/),[ml] / [kg·min],0.58,5529,DB04576,Fleroxacin
,2499248,dialysate/plasma concentration ratio,"In patients on continuous ambulatory peritoneal dialysis the mean dialysate/plasma concentration ratio of fleroxacin increased from 0.52 +/- 0.11 to 0.71 +/- 0.13 (P less than 0.001) with increasing dwell time, resulting in a 7.8 +/- 3.6% recovery of unchanged fleroxacin in peritoneal dialysate.",Pharmacokinetics and metabolism of intravenous and oral fleroxacin in subjects with normal and impaired renal function and in patients on continuous ambulatory peritoneal dialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2499248/),,0.52,5530,DB04576,Fleroxacin
,2499248,dialysate/plasma concentration ratio,"In patients on continuous ambulatory peritoneal dialysis the mean dialysate/plasma concentration ratio of fleroxacin increased from 0.52 +/- 0.11 to 0.71 +/- 0.13 (P less than 0.001) with increasing dwell time, resulting in a 7.8 +/- 3.6% recovery of unchanged fleroxacin in peritoneal dialysate.",Pharmacokinetics and metabolism of intravenous and oral fleroxacin in subjects with normal and impaired renal function and in patients on continuous ambulatory peritoneal dialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2499248/),,0.71,5531,DB04576,Fleroxacin
,3144533,elimination half-life,"The characteristics of this new trifluorinated quinolone are the long elimination half-life of approximately 10 h and the high plasma concentrations, which exceed 2 mg/l after an oral dose of 200 mg.",Single and multiple dose pharmacokinetics of fleroxacin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3144533/),h,10,6873,DB04576,Fleroxacin
exceeded,3144533,volume of distribution (Vss),The volume of distribution (Vss) exceeded 1 l/kg and reflects the good tissue penetration.,Single and multiple dose pharmacokinetics of fleroxacin. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3144533/),[l] / [kg],1,6874,DB04576,Fleroxacin
,3144533,Renal clearance of unbound drug,Renal clearance of unbound drug was 104 ml/min and within three days 56% of the dose could be recovered from urine as unchanged drug.,Single and multiple dose pharmacokinetics of fleroxacin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3144533/),[ml] / [min],104,6875,DB04576,Fleroxacin
,3144533,F,The administered tablets were completely bioavailable (F = 1.0) and a significant first pass metabolism can therefore be excluded.,Single and multiple dose pharmacokinetics of fleroxacin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3144533/),,1.0,6876,DB04576,Fleroxacin
,9661000,total urinary recovery,The total urinary recovery of pefloxacin and the active metabolite norfloxacin was 34%.,Urinary excretion and bactericidal activities of a single oral dose of 400 milligrams of fleroxacin versus a single oral dose of 800 milligrams of pefloxacin in healthy volunteers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661000/),%,34,12488,DB04576,Fleroxacin
,9661000,MIC,Against Escherichia coli ATCC 25922 the median UBTs were similar for both antibiotics and at least 1:8 for 96 h; against the E. coli strain for which the MIC was 0.5 microgram/ml the UBT was at least 1:4 for 48 h.,Urinary excretion and bactericidal activities of a single oral dose of 400 milligrams of fleroxacin versus a single oral dose of 800 milligrams of pefloxacin in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661000/),[μg] / [ml],0.5,12489,DB04576,Fleroxacin
,9661000,UBT,Against Escherichia coli ATCC 25922 the median UBTs were similar for both antibiotics and at least 1:8 for 96 h; against the E. coli strain for which the MIC was 0.5 microgram/ml the UBT was at least 1:4 for 48 h.,Urinary excretion and bactericidal activities of a single oral dose of 400 milligrams of fleroxacin versus a single oral dose of 800 milligrams of pefloxacin in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661000/),,1,12490,DB04576,Fleroxacin
,9661000,UBTs,The UBTs of both drugs against Klebsiella pneumoniae were at least 1:16 for 72 h.,Urinary excretion and bactericidal activities of a single oral dose of 400 milligrams of fleroxacin versus a single oral dose of 800 milligrams of pefloxacin in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661000/),,1:16,12491,DB04576,Fleroxacin
,9661000,MIC,"The UBTs for Staphylococcus aureus (the MIC for which was 16 micrograms/ml) of both antibiotics were low, and in some of the samples, no bactericidal titers were observed.",Urinary excretion and bactericidal activities of a single oral dose of 400 milligrams of fleroxacin versus a single oral dose of 800 milligrams of pefloxacin in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661000/),[μg] / [ml],16,12492,DB04576,Fleroxacin
,10606835,sputum to plasma ratios,The mean sputum to plasma ratios of both ciprofloxacin and fleroxacin were approximately 1 on both days 1 and 3.,The pharmacokinetics of oral fleroxacin and ciprofloxacin in plasma and sputum during acute and chronic dosing. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10606835/),,1,24771,DB04576,Fleroxacin
,10606835,accumulation index,Fleroxacin accumulated in plasma (accumulation index 1.52+/-0.07) and sputum (accumulation index 1.79+/-0.39) from day 1 to day 3.,The pharmacokinetics of oral fleroxacin and ciprofloxacin in plasma and sputum during acute and chronic dosing. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10606835/),,1.52,24772,DB04576,Fleroxacin
,10606835,accumulation index,Fleroxacin accumulated in plasma (accumulation index 1.52+/-0.07) and sputum (accumulation index 1.79+/-0.39) from day 1 to day 3.,The pharmacokinetics of oral fleroxacin and ciprofloxacin in plasma and sputum during acute and chronic dosing. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10606835/),,1.79,24773,DB04576,Fleroxacin
,10606835,half life,Accumulation did not occur for ciprofloxacin because the dose interval (12 h) was considerable longer than its half life (3-4 h).,The pharmacokinetics of oral fleroxacin and ciprofloxacin in plasma and sputum during acute and chronic dosing. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10606835/),h,3-4,24774,DB04576,Fleroxacin
,10606835,sputum to plasma ratio,The sputum to plasma ratio of ciprofloxacin and fleroxacin is approximately 1.,The pharmacokinetics of oral fleroxacin and ciprofloxacin in plasma and sputum during acute and chronic dosing. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10606835/),,1,24775,DB04576,Fleroxacin
less,2109576,excretion ratios,"In dogs, on the other hand, the excretion ratios were less than unity (0.608 and 0.456) both without and with probenecid, and so were not affected by probenecid.","Renal handling of fleroxacin in rabbits, dogs, and humans. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2109576/),,0.608,26050,DB04576,Fleroxacin
,2109576,excretion ratios,"In dogs, on the other hand, the excretion ratios were less than unity (0.608 and 0.456) both without and with probenecid, and so were not affected by probenecid.","Renal handling of fleroxacin in rabbits, dogs, and humans. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2109576/),,0.456,26051,DB04576,Fleroxacin
,2109576,excretion ratio,"The excretion ratio without probenecid was 1.13, which was significantly decreased to 0.750 with probenecid.","Renal handling of fleroxacin in rabbits, dogs, and humans. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2109576/),,1.13,26052,DB04576,Fleroxacin
,2109576,excretion ratio,"The excretion ratio without probenecid was 1.13, which was significantly decreased to 0.750 with probenecid.","Renal handling of fleroxacin in rabbits, dogs, and humans. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2109576/),,0.750,26053,DB04576,Fleroxacin
,2509411,Peak fleroxacin,"Peak fleroxacin and pefloxacin concentrations in the serum of the infected animals were 14.6 +/- 4.7 mg/l and 13 +/- 2.9 mg/l respectively, peak fleroxacin and pefloxacin abscess fluid concentrations after 24 h were 12.3 +/- 2.5 mg/l and 8.9 +/- 2.2 mg/l, respectively (85% and 68% of peak serum concentrations).",The pharmacokinetics and therapeutic efficacy of fleroxacin and pefloxacin in a rat abscess model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2509411/),[mg] / [l],14.6,36167,DB04576,Fleroxacin
,2509411,concentrations,"Peak fleroxacin and pefloxacin concentrations in the serum of the infected animals were 14.6 +/- 4.7 mg/l and 13 +/- 2.9 mg/l respectively, peak fleroxacin and pefloxacin abscess fluid concentrations after 24 h were 12.3 +/- 2.5 mg/l and 8.9 +/- 2.2 mg/l, respectively (85% and 68% of peak serum concentrations).",The pharmacokinetics and therapeutic efficacy of fleroxacin and pefloxacin in a rat abscess model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2509411/),[mg] / [l],13,36168,DB04576,Fleroxacin
,2509411,peak fleroxacin,"Peak fleroxacin and pefloxacin concentrations in the serum of the infected animals were 14.6 +/- 4.7 mg/l and 13 +/- 2.9 mg/l respectively, peak fleroxacin and pefloxacin abscess fluid concentrations after 24 h were 12.3 +/- 2.5 mg/l and 8.9 +/- 2.2 mg/l, respectively (85% and 68% of peak serum concentrations).",The pharmacokinetics and therapeutic efficacy of fleroxacin and pefloxacin in a rat abscess model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2509411/),[mg] / [l],12.3,36169,DB04576,Fleroxacin
,2509411,abscess fluid concentrations,"Peak fleroxacin and pefloxacin concentrations in the serum of the infected animals were 14.6 +/- 4.7 mg/l and 13 +/- 2.9 mg/l respectively, peak fleroxacin and pefloxacin abscess fluid concentrations after 24 h were 12.3 +/- 2.5 mg/l and 8.9 +/- 2.2 mg/l, respectively (85% and 68% of peak serum concentrations).",The pharmacokinetics and therapeutic efficacy of fleroxacin and pefloxacin in a rat abscess model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2509411/),[mg] / [l],8.9,36170,DB04576,Fleroxacin
,2509411,abscess fluid concentrations,"Peak fleroxacin and pefloxacin concentrations in the serum of the infected animals were 14.6 +/- 4.7 mg/l and 13 +/- 2.9 mg/l respectively, peak fleroxacin and pefloxacin abscess fluid concentrations after 24 h were 12.3 +/- 2.5 mg/l and 8.9 +/- 2.2 mg/l, respectively (85% and 68% of peak serum concentrations).",The pharmacokinetics and therapeutic efficacy of fleroxacin and pefloxacin in a rat abscess model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2509411/),,85,36171,DB04576,Fleroxacin
,2509411,Abscess fluid concentrations,Abscess fluid concentrations at 96 h were: fleroxacin 4.7 +/- 2.6 mg/l and pefloxacin 4.5 +/- 1.7 mg/l.,The pharmacokinetics and therapeutic efficacy of fleroxacin and pefloxacin in a rat abscess model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2509411/),[mg] / [l],4.7,36172,DB04576,Fleroxacin
,2509411,Abscess fluid concentrations,Abscess fluid concentrations at 96 h were: fleroxacin 4.7 +/- 2.6 mg/l and pefloxacin 4.5 +/- 1.7 mg/l.,The pharmacokinetics and therapeutic efficacy of fleroxacin and pefloxacin in a rat abscess model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2509411/),[mg] / [l],4.5,36173,DB04576,Fleroxacin
,2088195,peak titers,"In general, against anaerobic bacteria, low bactericidal activities were determined in both studies (mean peak titers ranged from 1:2.1 to 1:3.1; mean trough titers range from 1:2.0 to 1:2.9).","Pharmacokinetics and serum bactericidal activities of quinolones in combination with clindamycin, metronidazole, and ornidazole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2088195/),,1,38429,DB04576,Fleroxacin
,2088195,peak titers,"In general, against anaerobic bacteria, low bactericidal activities were determined in both studies (mean peak titers ranged from 1:2.1 to 1:3.1; mean trough titers range from 1:2.0 to 1:2.9).","Pharmacokinetics and serum bactericidal activities of quinolones in combination with clindamycin, metronidazole, and ornidazole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2088195/),,2.1,38430,DB04576,Fleroxacin
,2088195,peak titers,"In general, against anaerobic bacteria, low bactericidal activities were determined in both studies (mean peak titers ranged from 1:2.1 to 1:3.1; mean trough titers range from 1:2.0 to 1:2.9).","Pharmacokinetics and serum bactericidal activities of quinolones in combination with clindamycin, metronidazole, and ornidazole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2088195/),,3.1,38431,DB04576,Fleroxacin
,2088195,trough titers,"In general, against anaerobic bacteria, low bactericidal activities were determined in both studies (mean peak titers ranged from 1:2.1 to 1:3.1; mean trough titers range from 1:2.0 to 1:2.9).","Pharmacokinetics and serum bactericidal activities of quinolones in combination with clindamycin, metronidazole, and ornidazole. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2088195/),,1,38432,DB04576,Fleroxacin
,2088195,trough titers,"In general, against anaerobic bacteria, low bactericidal activities were determined in both studies (mean peak titers ranged from 1:2.1 to 1:3.1; mean trough titers range from 1:2.0 to 1:2.9).","Pharmacokinetics and serum bactericidal activities of quinolones in combination with clindamycin, metronidazole, and ornidazole. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2088195/),,2.0,38433,DB04576,Fleroxacin
,2088195,trough titers,"In general, against anaerobic bacteria, low bactericidal activities were determined in both studies (mean peak titers ranged from 1:2.1 to 1:3.1; mean trough titers range from 1:2.0 to 1:2.9).","Pharmacokinetics and serum bactericidal activities of quinolones in combination with clindamycin, metronidazole, and ornidazole. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2088195/),,2.9,38434,DB04576,Fleroxacin
,8092817,maximum concentration,"There were no significant changes in the following pharmacokinetic parameters (mean standard deviation) the maximum concentration of drug in serum (6.4 +/- 1.5 versus 6.7 +/- 1.9 mg/liter), the minimum concentration of drug in serum, defined as the concentration of drug in serum at 24 h postdose (3.0 +/- 1.7 versus 2.5 +/- 1.2 mg/liter), the time to the maximum concentration of drug in serum (2.3 +/- 1.4 versus 2.0 +/- 1.2 h), and the elimination half-life (19.7 +/- 8.0 versus 17.9 +/- 6.9 h).",Single-dose pharmacokinetics of oral fleroxacin in bacteremic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8092817/),[mg] / [l],6.4,41616,DB04576,Fleroxacin
,8092817,maximum concentration,"There were no significant changes in the following pharmacokinetic parameters (mean standard deviation) the maximum concentration of drug in serum (6.4 +/- 1.5 versus 6.7 +/- 1.9 mg/liter), the minimum concentration of drug in serum, defined as the concentration of drug in serum at 24 h postdose (3.0 +/- 1.7 versus 2.5 +/- 1.2 mg/liter), the time to the maximum concentration of drug in serum (2.3 +/- 1.4 versus 2.0 +/- 1.2 h), and the elimination half-life (19.7 +/- 8.0 versus 17.9 +/- 6.9 h).",Single-dose pharmacokinetics of oral fleroxacin in bacteremic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8092817/),[mg] / [l],6.7,41617,DB04576,Fleroxacin
,8092817,minimum concentration of drug,"There were no significant changes in the following pharmacokinetic parameters (mean standard deviation) the maximum concentration of drug in serum (6.4 +/- 1.5 versus 6.7 +/- 1.9 mg/liter), the minimum concentration of drug in serum, defined as the concentration of drug in serum at 24 h postdose (3.0 +/- 1.7 versus 2.5 +/- 1.2 mg/liter), the time to the maximum concentration of drug in serum (2.3 +/- 1.4 versus 2.0 +/- 1.2 h), and the elimination half-life (19.7 +/- 8.0 versus 17.9 +/- 6.9 h).",Single-dose pharmacokinetics of oral fleroxacin in bacteremic patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8092817/),[mg] / [l],3.0,41618,DB04576,Fleroxacin
,8092817,minimum concentration of drug,"There were no significant changes in the following pharmacokinetic parameters (mean standard deviation) the maximum concentration of drug in serum (6.4 +/- 1.5 versus 6.7 +/- 1.9 mg/liter), the minimum concentration of drug in serum, defined as the concentration of drug in serum at 24 h postdose (3.0 +/- 1.7 versus 2.5 +/- 1.2 mg/liter), the time to the maximum concentration of drug in serum (2.3 +/- 1.4 versus 2.0 +/- 1.2 h), and the elimination half-life (19.7 +/- 8.0 versus 17.9 +/- 6.9 h).",Single-dose pharmacokinetics of oral fleroxacin in bacteremic patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8092817/),[mg] / [l],2.5,41619,DB04576,Fleroxacin
,8092817,time to the maximum concentration,"There were no significant changes in the following pharmacokinetic parameters (mean standard deviation) the maximum concentration of drug in serum (6.4 +/- 1.5 versus 6.7 +/- 1.9 mg/liter), the minimum concentration of drug in serum, defined as the concentration of drug in serum at 24 h postdose (3.0 +/- 1.7 versus 2.5 +/- 1.2 mg/liter), the time to the maximum concentration of drug in serum (2.3 +/- 1.4 versus 2.0 +/- 1.2 h), and the elimination half-life (19.7 +/- 8.0 versus 17.9 +/- 6.9 h).",Single-dose pharmacokinetics of oral fleroxacin in bacteremic patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8092817/),h,2.3,41620,DB04576,Fleroxacin
,8092817,time to the maximum concentration,"There were no significant changes in the following pharmacokinetic parameters (mean standard deviation) the maximum concentration of drug in serum (6.4 +/- 1.5 versus 6.7 +/- 1.9 mg/liter), the minimum concentration of drug in serum, defined as the concentration of drug in serum at 24 h postdose (3.0 +/- 1.7 versus 2.5 +/- 1.2 mg/liter), the time to the maximum concentration of drug in serum (2.3 +/- 1.4 versus 2.0 +/- 1.2 h), and the elimination half-life (19.7 +/- 8.0 versus 17.9 +/- 6.9 h).",Single-dose pharmacokinetics of oral fleroxacin in bacteremic patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8092817/),h,2.0,41621,DB04576,Fleroxacin
,8092817,elimination half-life,"There were no significant changes in the following pharmacokinetic parameters (mean standard deviation) the maximum concentration of drug in serum (6.4 +/- 1.5 versus 6.7 +/- 1.9 mg/liter), the minimum concentration of drug in serum, defined as the concentration of drug in serum at 24 h postdose (3.0 +/- 1.7 versus 2.5 +/- 1.2 mg/liter), the time to the maximum concentration of drug in serum (2.3 +/- 1.4 versus 2.0 +/- 1.2 h), and the elimination half-life (19.7 +/- 8.0 versus 17.9 +/- 6.9 h).",Single-dose pharmacokinetics of oral fleroxacin in bacteremic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8092817/),h,19.7,41622,DB04576,Fleroxacin
,8092817,elimination half-life,"There were no significant changes in the following pharmacokinetic parameters (mean standard deviation) the maximum concentration of drug in serum (6.4 +/- 1.5 versus 6.7 +/- 1.9 mg/liter), the minimum concentration of drug in serum, defined as the concentration of drug in serum at 24 h postdose (3.0 +/- 1.7 versus 2.5 +/- 1.2 mg/liter), the time to the maximum concentration of drug in serum (2.3 +/- 1.4 versus 2.0 +/- 1.2 h), and the elimination half-life (19.7 +/- 8.0 versus 17.9 +/- 6.9 h).",Single-dose pharmacokinetics of oral fleroxacin in bacteremic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8092817/),h,17.9,41623,DB04576,Fleroxacin
,8092817,oral clearance,"Oral clearance of fleroxacin (CL = CL/F, where F is bioavailability was slightly, but not significantly, reduced during the bacteremic phase (oral clearance, 43.8+/- 23.5 versus 48.5 +/- 17.5 ml/min.).",Single-dose pharmacokinetics of oral fleroxacin in bacteremic patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8092817/),[ml] / [min],43.8,41624,DB04576,Fleroxacin
,8092817,oral clearance,"Oral clearance of fleroxacin (CL = CL/F, where F is bioavailability was slightly, but not significantly, reduced during the bacteremic phase (oral clearance, 43.8+/- 23.5 versus 48.5 +/- 17.5 ml/min.).",Single-dose pharmacokinetics of oral fleroxacin in bacteremic patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8092817/),[ml] / [min],48.5,41625,DB04576,Fleroxacin
,3142338,peak levels,The peak levels of fleroxacin in plasma were significantly higher after multiple dosing of 800 mg (14.3 versus 8.2 micrograms/ml; P less than 0.01) but not after the last 400-mg dose (6.7 versus 5.0 micrograms/ml).,Pharmacokinetics and tissue penetration of fleroxacin after single and multiple 400- and 800-mg-dosage regimens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3142338/),[μg] / [ml],14.3,43436,DB04576,Fleroxacin
,3142338,peak levels,The peak levels of fleroxacin in plasma were significantly higher after multiple dosing of 800 mg (14.3 versus 8.2 micrograms/ml; P less than 0.01) but not after the last 400-mg dose (6.7 versus 5.0 micrograms/ml).,Pharmacokinetics and tissue penetration of fleroxacin after single and multiple 400- and 800-mg-dosage regimens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3142338/),[μg] / [ml],8.2,43437,DB04576,Fleroxacin
,3142338,peak levels,The peak levels of fleroxacin in plasma were significantly higher after multiple dosing of 800 mg (14.3 versus 8.2 micrograms/ml; P less than 0.01) but not after the last 400-mg dose (6.7 versus 5.0 micrograms/ml).,Pharmacokinetics and tissue penetration of fleroxacin after single and multiple 400- and 800-mg-dosage regimens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3142338/),[μg] / [ml],6.7,43438,DB04576,Fleroxacin
,3142338,peak levels,The peak levels of fleroxacin in plasma were significantly higher after multiple dosing of 800 mg (14.3 versus 8.2 micrograms/ml; P less than 0.01) but not after the last 400-mg dose (6.7 versus 5.0 micrograms/ml).,Pharmacokinetics and tissue penetration of fleroxacin after single and multiple 400- and 800-mg-dosage regimens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3142338/),[μg] / [ml],5.0,43439,DB04576,Fleroxacin
,3142338,elimination half-life,"Increased elimination half-life occurred after multiple dosing of 800 mg, from 13.45 +/- 2.94 to 15.60 +/- 3.16 h (P less than 0.05).",Pharmacokinetics and tissue penetration of fleroxacin after single and multiple 400- and 800-mg-dosage regimens. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3142338/),h,13.45,43440,DB04576,Fleroxacin
,3142338,elimination half-life,"Increased elimination half-life occurred after multiple dosing of 800 mg, from 13.45 +/- 2.94 to 15.60 +/- 3.16 h (P less than 0.05).",Pharmacokinetics and tissue penetration of fleroxacin after single and multiple 400- and 800-mg-dosage regimens. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3142338/),h,15.60,43441,DB04576,Fleroxacin
,3142338,peak concentrations,"Mean peak concentrations in blister fluid were significantly different when the first (3.7 +/- 0.8 and 7.7 +/- 1.8 micrograms/ml for 400 and 800 mg, respectively) and last (5.7 +/- 0.9 and 12.3 +/- 2.1 micrograms/ml for 400 and 800 mg, respectively) doses were compared (P less than 0.01).",Pharmacokinetics and tissue penetration of fleroxacin after single and multiple 400- and 800-mg-dosage regimens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3142338/),[μg] / [ml],3.7,43442,DB04576,Fleroxacin
,3142338,peak concentrations,"Mean peak concentrations in blister fluid were significantly different when the first (3.7 +/- 0.8 and 7.7 +/- 1.8 micrograms/ml for 400 and 800 mg, respectively) and last (5.7 +/- 0.9 and 12.3 +/- 2.1 micrograms/ml for 400 and 800 mg, respectively) doses were compared (P less than 0.01).",Pharmacokinetics and tissue penetration of fleroxacin after single and multiple 400- and 800-mg-dosage regimens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3142338/),[μg] / [ml],7.7,43443,DB04576,Fleroxacin
,3142338,peak concentrations,"Mean peak concentrations in blister fluid were significantly different when the first (3.7 +/- 0.8 and 7.7 +/- 1.8 micrograms/ml for 400 and 800 mg, respectively) and last (5.7 +/- 0.9 and 12.3 +/- 2.1 micrograms/ml for 400 and 800 mg, respectively) doses were compared (P less than 0.01).",Pharmacokinetics and tissue penetration of fleroxacin after single and multiple 400- and 800-mg-dosage regimens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3142338/),[μg] / [ml],5.7,43444,DB04576,Fleroxacin
,3142338,peak concentrations,"Mean peak concentrations in blister fluid were significantly different when the first (3.7 +/- 0.8 and 7.7 +/- 1.8 micrograms/ml for 400 and 800 mg, respectively) and last (5.7 +/- 0.9 and 12.3 +/- 2.1 micrograms/ml for 400 and 800 mg, respectively) doses were compared (P less than 0.01).",Pharmacokinetics and tissue penetration of fleroxacin after single and multiple 400- and 800-mg-dosage regimens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3142338/),[μg] / [ml],12.3,43445,DB04576,Fleroxacin
,3142338,cleared,"After multiple administration of 800 mg, fleroxacin was cleared from the body more slowly: from 98.80 ml/min after a single dose to 77.72 ml/min following 800 mg every 24 h (P less than 0.01).",Pharmacokinetics and tissue penetration of fleroxacin after single and multiple 400- and 800-mg-dosage regimens. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3142338/),[ml] / [min],98.80,43446,DB04576,Fleroxacin
,3142338,cleared,"After multiple administration of 800 mg, fleroxacin was cleared from the body more slowly: from 98.80 ml/min after a single dose to 77.72 ml/min following 800 mg every 24 h (P less than 0.01).",Pharmacokinetics and tissue penetration of fleroxacin after single and multiple 400- and 800-mg-dosage regimens. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3142338/),[ml] / [min],77.72,43447,DB04576,Fleroxacin
more,1511632,recovery,This method yielded a high recovery of more than 85%.,Penetration of fleroxacin into human and animal tissues. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1511632/),%,85,52447,DB04576,Fleroxacin
,1511632,peak concentrations,"Following oral administration of the recommended therapeutic dose of 400 mg, once daily, peak concentrations of 5-6 mg/l were reached in human plasma at steady state.",Penetration of fleroxacin into human and animal tissues. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1511632/),[mg] / [l],5-6,52448,DB04576,Fleroxacin
,9124826,AUCtissue/AUCserum ratios,"For cefodizime and cefpirome, the AUCtissue/AUCserum ratios were 0.12 to 0.35 and 1.20 to 1.79, respectively.",Characterization of peripheral-compartment kinetics of antibiotics by in vivo microdialysis in humans. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9124826/),,0,56896,DB04576,Fleroxacin
,9124826,AUCtissue/AUCserum ratios,The AUCtissue/AUCserum ratios were 0.34 to 0.38 for fleroxacin and 0.42 to 0.49 for dirithromycin.,Characterization of peripheral-compartment kinetics of antibiotics by in vivo microdialysis in humans. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9124826/),,0.34 to 0.38,56897,DB04576,Fleroxacin
,9124826,AUCtissue/AUCserum ratios,The AUCtissue/AUCserum ratios were 0.34 to 0.38 for fleroxacin and 0.42 to 0.49 for dirithromycin.,Characterization of peripheral-compartment kinetics of antibiotics by in vivo microdialysis in humans. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9124826/),,0.42 to 0.49,56898,DB04576,Fleroxacin
,3144534,AUC-,The high AUC-value of 60.4 +/- 8.4 mg.h/l is the result of complete absorption and the long half-life of 10.8 +/- 1.6 h.,Pharmacokinetics and body fluid penetration of fleroxacin in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3144534/),[h·mg] / [l],60.4,57999,DB04576,Fleroxacin
,3144534,half-life,The high AUC-value of 60.4 +/- 8.4 mg.h/l is the result of complete absorption and the long half-life of 10.8 +/- 1.6 h.,Pharmacokinetics and body fluid penetration of fleroxacin in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3144534/),h,10.8,58000,DB04576,Fleroxacin
,3144534,total,"The total, renal and non-renal clearance of fleroxacin were 107.9 +/- 15.1, 67.6 +/- 11.8 and 40.3 +/- 14.5 ml/min respectively.",Pharmacokinetics and body fluid penetration of fleroxacin in healthy volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3144534/),[ml] / [min],107.9,58001,DB04576,Fleroxacin
,3144534,renal,"The total, renal and non-renal clearance of fleroxacin were 107.9 +/- 15.1, 67.6 +/- 11.8 and 40.3 +/- 14.5 ml/min respectively.",Pharmacokinetics and body fluid penetration of fleroxacin in healthy volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3144534/),[ml] / [min],67.6,58002,DB04576,Fleroxacin
,3144534,non-renal clearance,"The total, renal and non-renal clearance of fleroxacin were 107.9 +/- 15.1, 67.6 +/- 11.8 and 40.3 +/- 14.5 ml/min respectively.",Pharmacokinetics and body fluid penetration of fleroxacin in healthy volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3144534/),[ml] / [min],40.3,58003,DB04576,Fleroxacin
,3144534,volume of distribution Vd beta/F,The volume of distribution Vd beta/F was 101.4 +/- 21.9 or 1.32 +/- 0.28 l/kg.,Pharmacokinetics and body fluid penetration of fleroxacin in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3144534/),[l] / [kg],101.4,58004,DB04576,Fleroxacin
,3144534,volume of distribution Vd beta/F,The volume of distribution Vd beta/F was 101.4 +/- 21.9 or 1.32 +/- 0.28 l/kg.,Pharmacokinetics and body fluid penetration of fleroxacin in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3144534/),[l] / [kg],1.32,58005,DB04576,Fleroxacin
,8452184,serum half-life,Its long serum half-life (8-12 hours) allows once-a-day dosing.,Overview of the pharmacokinetics of fleroxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8452184/),h,8-12,58610,DB04576,Fleroxacin
,10963305,maximum serum concentration (Cmax),Following intravenous administration the maximum serum concentration (Cmax) was 2.7+/-1.06mg/l for ciprofioxacin and 0.99+/-0.41 mg/l for fleroxacin; the area under the blood level curve (AUC) was 8.82+/-3.19 mg x h/l with ciprofloxacin and 8.52+/-3.83 mg x h/l with fleroxacin.,Bioavailability of ciprofloxacin and fleroxacin: results of a preliminary investigation in healthy adult Nigerian male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963305/),[mg] / [l],2.7,60409,DB04576,Fleroxacin
,10963305,maximum serum concentration (Cmax),Following intravenous administration the maximum serum concentration (Cmax) was 2.7+/-1.06mg/l for ciprofioxacin and 0.99+/-0.41 mg/l for fleroxacin; the area under the blood level curve (AUC) was 8.82+/-3.19 mg x h/l with ciprofloxacin and 8.52+/-3.83 mg x h/l with fleroxacin.,Bioavailability of ciprofloxacin and fleroxacin: results of a preliminary investigation in healthy adult Nigerian male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963305/),[mg] / [l],0.99,60410,DB04576,Fleroxacin
,10963305,area under the blood level curve (AUC),Following intravenous administration the maximum serum concentration (Cmax) was 2.7+/-1.06mg/l for ciprofioxacin and 0.99+/-0.41 mg/l for fleroxacin; the area under the blood level curve (AUC) was 8.82+/-3.19 mg x h/l with ciprofloxacin and 8.52+/-3.83 mg x h/l with fleroxacin.,Bioavailability of ciprofloxacin and fleroxacin: results of a preliminary investigation in healthy adult Nigerian male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963305/),[h·mg] / [l],8.82,60411,DB04576,Fleroxacin
,10963305,area under the blood level curve (AUC),Following intravenous administration the maximum serum concentration (Cmax) was 2.7+/-1.06mg/l for ciprofioxacin and 0.99+/-0.41 mg/l for fleroxacin; the area under the blood level curve (AUC) was 8.82+/-3.19 mg x h/l with ciprofloxacin and 8.52+/-3.83 mg x h/l with fleroxacin.,Bioavailability of ciprofloxacin and fleroxacin: results of a preliminary investigation in healthy adult Nigerian male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963305/),[h·mg] / [l],8.52,60412,DB04576,Fleroxacin
,10963305,Cmax,"Following oral administration the Cmax was 1.52+/-0.94 mg/l with ciprofloxacin and 0.57+/-0.08 mg/l with fleroxacin; the AUC was 9.87+/-4.10 and 7.55+/-1.42 mg x h/l, respectively.",Bioavailability of ciprofloxacin and fleroxacin: results of a preliminary investigation in healthy adult Nigerian male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963305/),[mg] / [l],1.52,60413,DB04576,Fleroxacin
,10963305,Cmax,"Following oral administration the Cmax was 1.52+/-0.94 mg/l with ciprofloxacin and 0.57+/-0.08 mg/l with fleroxacin; the AUC was 9.87+/-4.10 and 7.55+/-1.42 mg x h/l, respectively.",Bioavailability of ciprofloxacin and fleroxacin: results of a preliminary investigation in healthy adult Nigerian male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963305/),[mg] / [l],0.57,60414,DB04576,Fleroxacin
,10963305,AUC,"Following oral administration the Cmax was 1.52+/-0.94 mg/l with ciprofloxacin and 0.57+/-0.08 mg/l with fleroxacin; the AUC was 9.87+/-4.10 and 7.55+/-1.42 mg x h/l, respectively.",Bioavailability of ciprofloxacin and fleroxacin: results of a preliminary investigation in healthy adult Nigerian male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963305/),[h·mg] / [l],9.87,60415,DB04576,Fleroxacin
,10963305,AUC,"Following oral administration the Cmax was 1.52+/-0.94 mg/l with ciprofloxacin and 0.57+/-0.08 mg/l with fleroxacin; the AUC was 9.87+/-4.10 and 7.55+/-1.42 mg x h/l, respectively.",Bioavailability of ciprofloxacin and fleroxacin: results of a preliminary investigation in healthy adult Nigerian male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963305/),[h·mg] / [l],7.55,60416,DB04576,Fleroxacin
,10963305,absolute BA,The absolute BA following oral administration was found to be 0.79+/-0.47 for ciprofloxacin and 1.01+/-0.78 for fleroxacin.,Bioavailability of ciprofloxacin and fleroxacin: results of a preliminary investigation in healthy adult Nigerian male volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963305/),,0.79,60417,DB04576,Fleroxacin
,10963305,absolute BA,The absolute BA following oral administration was found to be 0.79+/-0.47 for ciprofloxacin and 1.01+/-0.78 for fleroxacin.,Bioavailability of ciprofloxacin and fleroxacin: results of a preliminary investigation in healthy adult Nigerian male volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963305/),,1.01,60418,DB04576,Fleroxacin
,10963305,renal clearance [Cl(r)],"When these BA results were corrected for renal clearance [Cl(r)] and elimination half-life (t1/2) the values were reduced to 0.37+/-0.17 and 0.31+/-0.18, respectively, for ciprofloxacin and 0.53+/-0.23 and 0.99+/-0.38, respectively, for fleroxacin.",Bioavailability of ciprofloxacin and fleroxacin: results of a preliminary investigation in healthy adult Nigerian male volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963305/),,0.37,60419,DB04576,Fleroxacin
,10963305,renal clearance [Cl(r)],"When these BA results were corrected for renal clearance [Cl(r)] and elimination half-life (t1/2) the values were reduced to 0.37+/-0.17 and 0.31+/-0.18, respectively, for ciprofloxacin and 0.53+/-0.23 and 0.99+/-0.38, respectively, for fleroxacin.",Bioavailability of ciprofloxacin and fleroxacin: results of a preliminary investigation in healthy adult Nigerian male volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963305/),,0.53,60420,DB04576,Fleroxacin
,10963305,elimination half-life (t1/2),"When these BA results were corrected for renal clearance [Cl(r)] and elimination half-life (t1/2) the values were reduced to 0.37+/-0.17 and 0.31+/-0.18, respectively, for ciprofloxacin and 0.53+/-0.23 and 0.99+/-0.38, respectively, for fleroxacin.",Bioavailability of ciprofloxacin and fleroxacin: results of a preliminary investigation in healthy adult Nigerian male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963305/),,0.31,60421,DB04576,Fleroxacin
,10963305,elimination half-life (t1/2),"When these BA results were corrected for renal clearance [Cl(r)] and elimination half-life (t1/2) the values were reduced to 0.37+/-0.17 and 0.31+/-0.18, respectively, for ciprofloxacin and 0.53+/-0.23 and 0.99+/-0.38, respectively, for fleroxacin.",Bioavailability of ciprofloxacin and fleroxacin: results of a preliminary investigation in healthy adult Nigerian male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963305/),,0.53,60422,DB04576,Fleroxacin
,10963305,elimination half-life (t1/2),"When these BA results were corrected for renal clearance [Cl(r)] and elimination half-life (t1/2) the values were reduced to 0.37+/-0.17 and 0.31+/-0.18, respectively, for ciprofloxacin and 0.53+/-0.23 and 0.99+/-0.38, respectively, for fleroxacin.",Bioavailability of ciprofloxacin and fleroxacin: results of a preliminary investigation in healthy adult Nigerian male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963305/),,0.99,60423,DB04576,Fleroxacin
,8257135,urinary output,The extent of hepatic enzyme induction by rifampin was confirmed by a significant increase of 6-beta-hydroxycortisol urinary output from 160.8 +/- 41.4 to 544.8 +/- 120.7 micrograms/4 h.,Influence of rifampin on fleroxacin pharmacokinetics. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),[μg] / [4·h],160.8,76179,DB04576,Fleroxacin
,8257135,urinary output,The extent of hepatic enzyme induction by rifampin was confirmed by a significant increase of 6-beta-hydroxycortisol urinary output from 160.8 +/- 41.4 to 544.8 +/- 120.7 micrograms/4 h.,Influence of rifampin on fleroxacin pharmacokinetics. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),[μg] / [4·h],544.8,76180,DB04576,Fleroxacin
,8257135,peak fleroxacin concentration,"There were no significant changes in the peak fleroxacin concentration in plasma (6.3 +/- 1.2 versus 6.2 +/- 1.9 mg/liter), time to maximum concentration of fleroxacin in plasma (1.1 +/- 0.9 versus 1.3 +/- 1.1 h), or renal clearance (58.3 +/- 16.4 versus 61.9 +/- 19.2 ml/min).",Influence of rifampin on fleroxacin pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),[mg] / [l],6.3,76181,DB04576,Fleroxacin
,8257135,peak fleroxacin concentration,"There were no significant changes in the peak fleroxacin concentration in plasma (6.3 +/- 1.2 versus 6.2 +/- 1.9 mg/liter), time to maximum concentration of fleroxacin in plasma (1.1 +/- 0.9 versus 1.3 +/- 1.1 h), or renal clearance (58.3 +/- 16.4 versus 61.9 +/- 19.2 ml/min).",Influence of rifampin on fleroxacin pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),[mg] / [l],6.2,76182,DB04576,Fleroxacin
,8257135,time to maximum concentration,"There were no significant changes in the peak fleroxacin concentration in plasma (6.3 +/- 1.2 versus 6.2 +/- 1.9 mg/liter), time to maximum concentration of fleroxacin in plasma (1.1 +/- 0.9 versus 1.3 +/- 1.1 h), or renal clearance (58.3 +/- 16.4 versus 61.9 +/- 19.2 ml/min).",Influence of rifampin on fleroxacin pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),h,1.1,76183,DB04576,Fleroxacin
,8257135,time to maximum concentration,"There were no significant changes in the peak fleroxacin concentration in plasma (6.3 +/- 1.2 versus 6.2 +/- 1.9 mg/liter), time to maximum concentration of fleroxacin in plasma (1.1 +/- 0.9 versus 1.3 +/- 1.1 h), or renal clearance (58.3 +/- 16.4 versus 61.9 +/- 19.2 ml/min).",Influence of rifampin on fleroxacin pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),h,1.3,76184,DB04576,Fleroxacin
,8257135,renal clearance,"There were no significant changes in the peak fleroxacin concentration in plasma (6.3 +/- 1.2 versus 6.2 +/- 1.9 mg/liter), time to maximum concentration of fleroxacin in plasma (1.1 +/- 0.9 versus 1.3 +/- 1.1 h), or renal clearance (58.3 +/- 16.4 versus 61.9 +/- 19.2 ml/min).",Influence of rifampin on fleroxacin pharmacokinetics. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),[ml] / [min],58.3,76185,DB04576,Fleroxacin
,8257135,renal clearance,"There were no significant changes in the peak fleroxacin concentration in plasma (6.3 +/- 1.2 versus 6.2 +/- 1.9 mg/liter), time to maximum concentration of fleroxacin in plasma (1.1 +/- 0.9 versus 1.3 +/- 1.1 h), or renal clearance (58.3 +/- 16.4 versus 61.9 +/- 19.2 ml/min).",Influence of rifampin on fleroxacin pharmacokinetics. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),[ml] / [min],61.9,76186,DB04576,Fleroxacin
,8257135,area under the curve AUC,"The area under the curve AUC (71.4 +/- 15.8 versus 62.2 +/- 13.7 mg.h/liter) and the terminal half-life of fleroxacin (11.4 +/- 2.2 versus 9.2 +/- 1.1 h) decreased (P < 0.05), while the total plasma clearance increased from 97.7 +/- 21.6 to 112.3 +/- 25.8 ml/min (P < 0.01).",Influence of rifampin on fleroxacin pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),[h·mg] / [l],71.4,76187,DB04576,Fleroxacin
,8257135,area under the curve AUC,"The area under the curve AUC (71.4 +/- 15.8 versus 62.2 +/- 13.7 mg.h/liter) and the terminal half-life of fleroxacin (11.4 +/- 2.2 versus 9.2 +/- 1.1 h) decreased (P < 0.05), while the total plasma clearance increased from 97.7 +/- 21.6 to 112.3 +/- 25.8 ml/min (P < 0.01).",Influence of rifampin on fleroxacin pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),[h·mg] / [l],62.2,76188,DB04576,Fleroxacin
,8257135,terminal half-life,"The area under the curve AUC (71.4 +/- 15.8 versus 62.2 +/- 13.7 mg.h/liter) and the terminal half-life of fleroxacin (11.4 +/- 2.2 versus 9.2 +/- 1.1 h) decreased (P < 0.05), while the total plasma clearance increased from 97.7 +/- 21.6 to 112.3 +/- 25.8 ml/min (P < 0.01).",Influence of rifampin on fleroxacin pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),h,11.4,76189,DB04576,Fleroxacin
,8257135,terminal half-life,"The area under the curve AUC (71.4 +/- 15.8 versus 62.2 +/- 13.7 mg.h/liter) and the terminal half-life of fleroxacin (11.4 +/- 2.2 versus 9.2 +/- 1.1 h) decreased (P < 0.05), while the total plasma clearance increased from 97.7 +/- 21.6 to 112.3 +/- 25.8 ml/min (P < 0.01).",Influence of rifampin on fleroxacin pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),h,9.2,76190,DB04576,Fleroxacin
,8257135,total plasma clearance,"The area under the curve AUC (71.4 +/- 15.8 versus 62.2 +/- 13.7 mg.h/liter) and the terminal half-life of fleroxacin (11.4 +/- 2.2 versus 9.2 +/- 1.1 h) decreased (P < 0.05), while the total plasma clearance increased from 97.7 +/- 21.6 to 112.3 +/- 25.8 ml/min (P < 0.01).",Influence of rifampin on fleroxacin pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),[ml] / [min],97.7,76191,DB04576,Fleroxacin
,8257135,total plasma clearance,"The area under the curve AUC (71.4 +/- 15.8 versus 62.2 +/- 13.7 mg.h/liter) and the terminal half-life of fleroxacin (11.4 +/- 2.2 versus 9.2 +/- 1.1 h) decreased (P < 0.05), while the total plasma clearance increased from 97.7 +/- 21.6 to 112.3 +/- 25.8 ml/min (P < 0.01).",Influence of rifampin on fleroxacin pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),[ml] / [min],112.3,76192,DB04576,Fleroxacin
,8257135,Metabolic clearance,"Metabolic clearance by N demethylation was increased ( 6.9 +/- 2.4 versus 12.5 +/- 3.2 ml/min; P < 0.01), whereas clearance by N oxidation did not change (5.8 +/- 1.1 versus 5.8 +/- 1.5 ml/min).",Influence of rifampin on fleroxacin pharmacokinetics. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),[ml] / [min],6.9,76193,DB04576,Fleroxacin
,8257135,Metabolic clearance,"Metabolic clearance by N demethylation was increased ( 6.9 +/- 2.4 versus 12.5 +/- 3.2 ml/min; P < 0.01), whereas clearance by N oxidation did not change (5.8 +/- 1.1 versus 5.8 +/- 1.5 ml/min).",Influence of rifampin on fleroxacin pharmacokinetics. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),[ml] / [min],12.5,76194,DB04576,Fleroxacin
,8257135,clearance,"Metabolic clearance by N demethylation was increased ( 6.9 +/- 2.4 versus 12.5 +/- 3.2 ml/min; P < 0.01), whereas clearance by N oxidation did not change (5.8 +/- 1.1 versus 5.8 +/- 1.5 ml/min).",Influence of rifampin on fleroxacin pharmacokinetics. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),[ml] / [min],5.8,76195,DB04576,Fleroxacin
,8257135,clearance,"Metabolic clearance by N demethylation was increased ( 6.9 +/- 2.4 versus 12.5 +/- 3.2 ml/min; P < 0.01), whereas clearance by N oxidation did not change (5.8 +/- 1.1 versus 5.8 +/- 1.5 ml/min).",Influence of rifampin on fleroxacin pharmacokinetics. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),[ml] / [min],5.8,76196,DB04576,Fleroxacin
,3141343,Tmax,There were no significant differences in Tmax (0.9 vs. 1.3 h) and in plasma elimination half-life (11.9 vs.,Comparative oral pharmacokinetics of fleroxacin and pefloxacin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141343/),h,0.9,86368,DB04576,Fleroxacin
,3141343,Tmax,There were no significant differences in Tmax (0.9 vs. 1.3 h) and in plasma elimination half-life (11.9 vs.,Comparative oral pharmacokinetics of fleroxacin and pefloxacin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141343/),h,1.3,86369,DB04576,Fleroxacin
,3141343,plasma elimination half-life,There were no significant differences in Tmax (0.9 vs. 1.3 h) and in plasma elimination half-life (11.9 vs.,Comparative oral pharmacokinetics of fleroxacin and pefloxacin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141343/),,11.9,86370,DB04576,Fleroxacin
,3141343,Cmax,"Cmax and AUC of fleroxacin were statistically significantly greater (P less than 0.05) compared to pefloxacin (Cmax: 5.62 vs. 4.09 mg/l, AUC0-48: 65.9 vs. 48.7 mg/l.h, AUC0-infinity: 70.7 vs. 51.5 mg/l.h).",Comparative oral pharmacokinetics of fleroxacin and pefloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141343/),[mg] / [l],5.62,86371,DB04576,Fleroxacin
,3141343,Cmax,"Cmax and AUC of fleroxacin were statistically significantly greater (P less than 0.05) compared to pefloxacin (Cmax: 5.62 vs. 4.09 mg/l, AUC0-48: 65.9 vs. 48.7 mg/l.h, AUC0-infinity: 70.7 vs. 51.5 mg/l.h).",Comparative oral pharmacokinetics of fleroxacin and pefloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141343/),[mg] / [l],4.09,86372,DB04576,Fleroxacin
,3141343,AUC0-48,"Cmax and AUC of fleroxacin were statistically significantly greater (P less than 0.05) compared to pefloxacin (Cmax: 5.62 vs. 4.09 mg/l, AUC0-48: 65.9 vs. 48.7 mg/l.h, AUC0-infinity: 70.7 vs. 51.5 mg/l.h).",Comparative oral pharmacokinetics of fleroxacin and pefloxacin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141343/),[mg] / [h·l],65.9,86373,DB04576,Fleroxacin
,3141343,AUC0-48,"Cmax and AUC of fleroxacin were statistically significantly greater (P less than 0.05) compared to pefloxacin (Cmax: 5.62 vs. 4.09 mg/l, AUC0-48: 65.9 vs. 48.7 mg/l.h, AUC0-infinity: 70.7 vs. 51.5 mg/l.h).",Comparative oral pharmacokinetics of fleroxacin and pefloxacin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141343/),[mg] / [h·l],48.7,86374,DB04576,Fleroxacin
,3141343,AUC0-infinity,"Cmax and AUC of fleroxacin were statistically significantly greater (P less than 0.05) compared to pefloxacin (Cmax: 5.62 vs. 4.09 mg/l, AUC0-48: 65.9 vs. 48.7 mg/l.h, AUC0-infinity: 70.7 vs. 51.5 mg/l.h).",Comparative oral pharmacokinetics of fleroxacin and pefloxacin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141343/),[mg] / [h·l],70.7,86375,DB04576,Fleroxacin
,3141343,AUC0-infinity,"Cmax and AUC of fleroxacin were statistically significantly greater (P less than 0.05) compared to pefloxacin (Cmax: 5.62 vs. 4.09 mg/l, AUC0-48: 65.9 vs. 48.7 mg/l.h, AUC0-infinity: 70.7 vs. 51.5 mg/l.h).",Comparative oral pharmacokinetics of fleroxacin and pefloxacin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141343/),[mg] / [h·l],51.5,86376,DB04576,Fleroxacin
,3141343,Renal clearances,Renal clearances of fleroxacin and pefloxacin were 51.8 and 11.7 ml/min respectively.,Comparative oral pharmacokinetics of fleroxacin and pefloxacin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141343/),[ml] / [min],51.8,86377,DB04576,Fleroxacin
,3141343,Renal clearances,Renal clearances of fleroxacin and pefloxacin were 51.8 and 11.7 ml/min respectively.,Comparative oral pharmacokinetics of fleroxacin and pefloxacin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141343/),[ml] / [min],11.7,86378,DB04576,Fleroxacin
,3141343,urine recovery,"The 48-h urine recovery was 48.6% for fleroxacin, 8.6% for pefloxacin, 7.1% and 17.4% for the N-demethyl metabolites, and 3.8% and 16.6% for the N-oxide metabolites of fleroxacin and pefloxacin respectively.",Comparative oral pharmacokinetics of fleroxacin and pefloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141343/),%,48.6,86379,DB04576,Fleroxacin
,3141343,urine recovery,"The 48-h urine recovery was 48.6% for fleroxacin, 8.6% for pefloxacin, 7.1% and 17.4% for the N-demethyl metabolites, and 3.8% and 16.6% for the N-oxide metabolites of fleroxacin and pefloxacin respectively.",Comparative oral pharmacokinetics of fleroxacin and pefloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141343/),%,8.6,86380,DB04576,Fleroxacin
,3141343,urine recovery,"The 48-h urine recovery was 48.6% for fleroxacin, 8.6% for pefloxacin, 7.1% and 17.4% for the N-demethyl metabolites, and 3.8% and 16.6% for the N-oxide metabolites of fleroxacin and pefloxacin respectively.",Comparative oral pharmacokinetics of fleroxacin and pefloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141343/),%,7.1,86381,DB04576,Fleroxacin
,3141343,urine recovery,"The 48-h urine recovery was 48.6% for fleroxacin, 8.6% for pefloxacin, 7.1% and 17.4% for the N-demethyl metabolites, and 3.8% and 16.6% for the N-oxide metabolites of fleroxacin and pefloxacin respectively.",Comparative oral pharmacokinetics of fleroxacin and pefloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141343/),%,17.4,86382,DB04576,Fleroxacin
,3141343,urine recovery,"The 48-h urine recovery was 48.6% for fleroxacin, 8.6% for pefloxacin, 7.1% and 17.4% for the N-demethyl metabolites, and 3.8% and 16.6% for the N-oxide metabolites of fleroxacin and pefloxacin respectively.",Comparative oral pharmacokinetics of fleroxacin and pefloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141343/),%,3.8,86383,DB04576,Fleroxacin
,3141343,urine recovery,"The 48-h urine recovery was 48.6% for fleroxacin, 8.6% for pefloxacin, 7.1% and 17.4% for the N-demethyl metabolites, and 3.8% and 16.6% for the N-oxide metabolites of fleroxacin and pefloxacin respectively.",Comparative oral pharmacokinetics of fleroxacin and pefloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141343/),%,16.6,86384,DB04576,Fleroxacin
,8452360,maximum concentration,"At approximately 2 h after oral administration, a maximum concentration of 5.6 mg/liter was determined in plasma; the area under the plasma concentration-time curve (AUC) amounted to 70.3 mg.h/liter, and the elimination half-life in the postdistributive phase was 8 h.",Penetration of fleroxacin into breast milk and pharmacokinetics in lactating women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8452360/),[mg] / [l],5.6,87054,DB04576,Fleroxacin
,8452360,area under the plasma concentration-time curve (AUC),"At approximately 2 h after oral administration, a maximum concentration of 5.6 mg/liter was determined in plasma; the area under the plasma concentration-time curve (AUC) amounted to 70.3 mg.h/liter, and the elimination half-life in the postdistributive phase was 8 h.",Penetration of fleroxacin into breast milk and pharmacokinetics in lactating women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8452360/),[h·mg] / [l],70.3,87055,DB04576,Fleroxacin
,8452360,elimination half-life,"At approximately 2 h after oral administration, a maximum concentration of 5.6 mg/liter was determined in plasma; the area under the plasma concentration-time curve (AUC) amounted to 70.3 mg.h/liter, and the elimination half-life in the postdistributive phase was 8 h.",Penetration of fleroxacin into breast milk and pharmacokinetics in lactating women. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8452360/),h,8,87056,DB04576,Fleroxacin
,8452360,Total systemic clearance,"Total systemic clearance was 97.3 ml/min, and urinary excretion was 38% of the dose within 48 h.",Penetration of fleroxacin into breast milk and pharmacokinetics in lactating women. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8452360/),[ml] / [min],97.3,87057,DB04576,Fleroxacin
,8452360,maximum concentration,"In breast milk, the mean maximum concentration was 3.5 mg/liter, which was reached 2.6 h after drug administration.",Penetration of fleroxacin into breast milk and pharmacokinetics in lactating women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8452360/),[mg] / [l],3.5,87058,DB04576,Fleroxacin
,8452360,AUC,"The elimination half-life of fleroxacin in milk was identical to that in plasma, and the AUC reached 43.3 mg.h/liter.",Penetration of fleroxacin into breast milk and pharmacokinetics in lactating women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8452360/),[h·mg] / [l],43.3,87059,DB04576,Fleroxacin
,8452360,cumulative excretion,The cumulative excretion in milk amounted to only 0.219 mg within 48 h.,Penetration of fleroxacin into breast milk and pharmacokinetics in lactating women. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8452360/),mg,0.219,87060,DB04576,Fleroxacin
,2121409,tmax,"By combining plasma analysis by high performance liquid chromatography with the magnetic resonance data, the following pharmacokinetic parameters (mean values) were obtained: tmax, 1.4, 4.6, and 5.6 hours in liver, plasma, and muscle, respectively; Cmax, 53, about 250, and about 60 mumol/L in plasma, liver, and muscle, respectively; t1/2, 4.4 hours (fast phase) and 10.8 hours (slow phase) in liver and 14.2 hours in plasma.",In vivo tissue pharmacokinetics by fluorine magnetic resonance spectroscopy: a study of liver and muscle disposition of fleroxacin in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2121409/),h,1.4,94643,DB04576,Fleroxacin
,2121409,tmax,"By combining plasma analysis by high performance liquid chromatography with the magnetic resonance data, the following pharmacokinetic parameters (mean values) were obtained: tmax, 1.4, 4.6, and 5.6 hours in liver, plasma, and muscle, respectively; Cmax, 53, about 250, and about 60 mumol/L in plasma, liver, and muscle, respectively; t1/2, 4.4 hours (fast phase) and 10.8 hours (slow phase) in liver and 14.2 hours in plasma.",In vivo tissue pharmacokinetics by fluorine magnetic resonance spectroscopy: a study of liver and muscle disposition of fleroxacin in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2121409/),h,4.6,94644,DB04576,Fleroxacin
,2121409,tmax,"By combining plasma analysis by high performance liquid chromatography with the magnetic resonance data, the following pharmacokinetic parameters (mean values) were obtained: tmax, 1.4, 4.6, and 5.6 hours in liver, plasma, and muscle, respectively; Cmax, 53, about 250, and about 60 mumol/L in plasma, liver, and muscle, respectively; t1/2, 4.4 hours (fast phase) and 10.8 hours (slow phase) in liver and 14.2 hours in plasma.",In vivo tissue pharmacokinetics by fluorine magnetic resonance spectroscopy: a study of liver and muscle disposition of fleroxacin in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2121409/),h,5.6,94645,DB04576,Fleroxacin
,2121409,Cmax,"By combining plasma analysis by high performance liquid chromatography with the magnetic resonance data, the following pharmacokinetic parameters (mean values) were obtained: tmax, 1.4, 4.6, and 5.6 hours in liver, plasma, and muscle, respectively; Cmax, 53, about 250, and about 60 mumol/L in plasma, liver, and muscle, respectively; t1/2, 4.4 hours (fast phase) and 10.8 hours (slow phase) in liver and 14.2 hours in plasma.",In vivo tissue pharmacokinetics by fluorine magnetic resonance spectroscopy: a study of liver and muscle disposition of fleroxacin in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2121409/),[μM] / [l],53,94646,DB04576,Fleroxacin
,2121409,Cmax,"By combining plasma analysis by high performance liquid chromatography with the magnetic resonance data, the following pharmacokinetic parameters (mean values) were obtained: tmax, 1.4, 4.6, and 5.6 hours in liver, plasma, and muscle, respectively; Cmax, 53, about 250, and about 60 mumol/L in plasma, liver, and muscle, respectively; t1/2, 4.4 hours (fast phase) and 10.8 hours (slow phase) in liver and 14.2 hours in plasma.",In vivo tissue pharmacokinetics by fluorine magnetic resonance spectroscopy: a study of liver and muscle disposition of fleroxacin in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2121409/),[μM] / [l],250,94647,DB04576,Fleroxacin
,2121409,Cmax,"By combining plasma analysis by high performance liquid chromatography with the magnetic resonance data, the following pharmacokinetic parameters (mean values) were obtained: tmax, 1.4, 4.6, and 5.6 hours in liver, plasma, and muscle, respectively; Cmax, 53, about 250, and about 60 mumol/L in plasma, liver, and muscle, respectively; t1/2, 4.4 hours (fast phase) and 10.8 hours (slow phase) in liver and 14.2 hours in plasma.",In vivo tissue pharmacokinetics by fluorine magnetic resonance spectroscopy: a study of liver and muscle disposition of fleroxacin in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2121409/),[μM] / [l],60,94648,DB04576,Fleroxacin
,2121409,t1/2,"By combining plasma analysis by high performance liquid chromatography with the magnetic resonance data, the following pharmacokinetic parameters (mean values) were obtained: tmax, 1.4, 4.6, and 5.6 hours in liver, plasma, and muscle, respectively; Cmax, 53, about 250, and about 60 mumol/L in plasma, liver, and muscle, respectively; t1/2, 4.4 hours (fast phase) and 10.8 hours (slow phase) in liver and 14.2 hours in plasma.",In vivo tissue pharmacokinetics by fluorine magnetic resonance spectroscopy: a study of liver and muscle disposition of fleroxacin in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2121409/),h,4.4,94649,DB04576,Fleroxacin
,2121409,t1/2,"By combining plasma analysis by high performance liquid chromatography with the magnetic resonance data, the following pharmacokinetic parameters (mean values) were obtained: tmax, 1.4, 4.6, and 5.6 hours in liver, plasma, and muscle, respectively; Cmax, 53, about 250, and about 60 mumol/L in plasma, liver, and muscle, respectively; t1/2, 4.4 hours (fast phase) and 10.8 hours (slow phase) in liver and 14.2 hours in plasma.",In vivo tissue pharmacokinetics by fluorine magnetic resonance spectroscopy: a study of liver and muscle disposition of fleroxacin in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2121409/),h,10.8,94650,DB04576,Fleroxacin
,2121409,t1/2,"By combining plasma analysis by high performance liquid chromatography with the magnetic resonance data, the following pharmacokinetic parameters (mean values) were obtained: tmax, 1.4, 4.6, and 5.6 hours in liver, plasma, and muscle, respectively; Cmax, 53, about 250, and about 60 mumol/L in plasma, liver, and muscle, respectively; t1/2, 4.4 hours (fast phase) and 10.8 hours (slow phase) in liver and 14.2 hours in plasma.",In vivo tissue pharmacokinetics by fluorine magnetic resonance spectroscopy: a study of liver and muscle disposition of fleroxacin in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2121409/),h,14.2,94651,DB04576,Fleroxacin
,8861529,half-life,"Fleroxacin is distinguished by its excellent bioavailability, high concentrations in the plasma and other body fluids, good tissue penetration, and a long half-life of 10-12 h, thus allowing once-a-day administration.",Fleroxacin overview. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8861529/),h,10-12,98573,DB04576,Fleroxacin
,9209780,MICs,The MICs of AM-1155 for 11 highly fluoroquinolone-resistant isolates with alterations in both GyrA and ParC ranged from 0.06 to 1.0 microgram/ml.,Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209780/),[μg] / [ml],0.06 to 1.0,104038,DB04576,Fleroxacin
,9209780,MICs inhibiting 50% (,"The MICs inhibiting 50% (MIC50) and 90% (MIC90) of these isolates were 0.125 and 1.0 microgram/ml, respectively.",Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209780/),[μg] / [ml],90,104039,DB04576,Fleroxacin
,9209780,MICs inhibiting 50% (,"The MICs inhibiting 50% (MIC50) and 90% (MIC90) of these isolates were 0.125 and 1.0 microgram/ml, respectively.",Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209780/),[μg] / [ml],0.125,104040,DB04576,Fleroxacin
,9209780,MIC50,"The MICs inhibiting 50% (MIC50) and 90% (MIC90) of these isolates were 0.125 and 1.0 microgram/ml, respectively.",Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209780/),[μg] / [ml],90,104041,DB04576,Fleroxacin
,9209780,MIC50,"The MICs inhibiting 50% (MIC50) and 90% (MIC90) of these isolates were 0.125 and 1.0 microgram/ml, respectively.",Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209780/),[μg] / [ml],0.125,104042,DB04576,Fleroxacin
,9209780,MIC90,"The MICs inhibiting 50% (MIC50) and 90% (MIC90) of these isolates were 0.125 and 1.0 microgram/ml, respectively.",Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209780/),[μg] / [ml],90,104043,DB04576,Fleroxacin
,9209780,MIC90,"The MICs inhibiting 50% (MIC50) and 90% (MIC90) of these isolates were 0.125 and 1.0 microgram/ml, respectively.",Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209780/),[μg] / [ml],1.0,104044,DB04576,Fleroxacin
,9209780,MICs,"The MICs of AM-1155 for 20 moderately fluoroquinolone-resistant isolates with alterations only in GyrA ranged from 0.03 to 0.25 microgram/ml (MIC50, 0.06 microgram/ml; MIC90m, 0.125 microgram/ml).",Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209780/),[μg] / [ml],0.03 to 0.25,104045,DB04576,Fleroxacin
,9209780,MIC50,"The MICs of AM-1155 for 20 moderately fluoroquinolone-resistant isolates with alterations only in GyrA ranged from 0.03 to 0.25 microgram/ml (MIC50, 0.06 microgram/ml; MIC90m, 0.125 microgram/ml).",Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209780/),[μg] / [ml],0.06,104046,DB04576,Fleroxacin
,9209780,MIC90m,"The MICs of AM-1155 for 20 moderately fluoroquinolone-resistant isolates with alterations only in GyrA ranged from 0.03 to 0.25 microgram/ml (MIC50, 0.06 microgram/ml; MIC90m, 0.125 microgram/ml).",Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209780/),[μg] / [ml],0.125,104047,DB04576,Fleroxacin
,9209780,MICs,"The MICs of AM-1155 for 24 of the quinolone-susceptible isolates without alterations in either GyrA or ParC ranged from 0.004 to 0.03 microgram/ml (MIC50, 0.008 microgram/ml. MIC90, 0.015 microgram/ml).",Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209780/),[μg] / [ml],0.004 to 0.03,104048,DB04576,Fleroxacin
,9209780,MIC50,"The MICs of AM-1155 for 24 of the quinolone-susceptible isolates without alterations in either GyrA or ParC ranged from 0.004 to 0.03 microgram/ml (MIC50, 0.008 microgram/ml. MIC90, 0.015 microgram/ml).",Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209780/),[μg] / [ml],0.008,104049,DB04576,Fleroxacin
,9209780,MIC90,"The MICs of AM-1155 for 24 of the quinolone-susceptible isolates without alterations in either GyrA or ParC ranged from 0.004 to 0.03 microgram/ml (MIC50, 0.008 microgram/ml. MIC90, 0.015 microgram/ml).",Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209780/),[μg] / [ml],0.015,104050,DB04576,Fleroxacin
,9209780,MICs,MICs for the causative organisms have ranged from 1.0 to 16.0 micrograms/ml.,Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209780/),[μg] / [ml],1.0 to 16.0,104051,DB04576,Fleroxacin
,9209780,MICs,"The MICs of AM-1155 for the isolates harboring quinolone resistance-associated genetic alterations, including strains exhibiting ciprofloxacin MICs of 2.0 and 8.0 micrograms/ml, still ranged from 0.03 to 1.0 microgram/mL A single-dose study in humans has demonstrated higher peak serum concentrations and longer half-lives of AM-1155, resulting in the AUC0-00 values of AM-1155, which are threefold greater than those of ciprofloxacin at the single doses of 400 and 600 mg.",Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209780/),[μg] / [ml],2.0,104052,DB04576,Fleroxacin
,9209780,MICs,"The MICs of AM-1155 for the isolates harboring quinolone resistance-associated genetic alterations, including strains exhibiting ciprofloxacin MICs of 2.0 and 8.0 micrograms/ml, still ranged from 0.03 to 1.0 microgram/mL A single-dose study in humans has demonstrated higher peak serum concentrations and longer half-lives of AM-1155, resulting in the AUC0-00 values of AM-1155, which are threefold greater than those of ciprofloxacin at the single doses of 400 and 600 mg.",Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209780/),[μg] / [ml],8.0,104053,DB04576,Fleroxacin
,9209780,MICs,"The MICs of AM-1155 for the isolates harboring quinolone resistance-associated genetic alterations, including strains exhibiting ciprofloxacin MICs of 2.0 and 8.0 micrograms/ml, still ranged from 0.03 to 1.0 microgram/mL A single-dose study in humans has demonstrated higher peak serum concentrations and longer half-lives of AM-1155, resulting in the AUC0-00 values of AM-1155, which are threefold greater than those of ciprofloxacin at the single doses of 400 and 600 mg.",Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209780/),[μg] / [ml],2.0,104054,DB04576,Fleroxacin
,9209780,MICs,"The MICs of AM-1155 for the isolates harboring quinolone resistance-associated genetic alterations, including strains exhibiting ciprofloxacin MICs of 2.0 and 8.0 micrograms/ml, still ranged from 0.03 to 1.0 microgram/mL A single-dose study in humans has demonstrated higher peak serum concentrations and longer half-lives of AM-1155, resulting in the AUC0-00 values of AM-1155, which are threefold greater than those of ciprofloxacin at the single doses of 400 and 600 mg.",Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209780/),[μg] / [ml],8.0,104055,DB04576,Fleroxacin
,9209780,MICs,"The MICs of AM-1155 for the isolates harboring quinolone resistance-associated genetic alterations, including strains exhibiting ciprofloxacin MICs of 2.0 and 8.0 micrograms/ml, still ranged from 0.03 to 1.0 microgram/mL A single-dose study in humans has demonstrated higher peak serum concentrations and longer half-lives of AM-1155, resulting in the AUC0-00 values of AM-1155, which are threefold greater than those of ciprofloxacin at the single doses of 400 and 600 mg.",Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209780/),[μg] / [ml],0.03 to 1.0,104056,DB04576,Fleroxacin
,11357519,peak concentration,HPLC analysis of the plasma concentrations in juvenile rats showed that the concentrations of trovafloxacin were considerably lower than those of the other fluoroquinolones that had been studied previously in our laboratory: the peak concentration of trovafloxacin was 14 +/- 2.9 mg/l (mean +/- SD) after a single dose of 600 mg/kg in juvenile rats.,Effects of fluoroquinolones on the locomotor activity in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11357519/),[mg] / [l],14,104393,DB04576,Fleroxacin
,11600365,MICs,"The MICs of E-4767 and E-5065 at which 90% of the isolates tested were inhibited (MIC(90)s) were 0.007 to 0.5 microg/ml and 0.03 to 2 microg/ml, respectively, for gram-positive organisms and <or=0.003 to 0.06 microg/ml and 0.007 to 0.12 microg/ml, respectively, for members of the family Enterobacteriaceae except Serratia marcescens and Providencia spp. (MIC(90)s of E-4767 and E-5065 for these species were <or=0.5 microg/ml and <or=2 microg/ml, respectively).","Antibacterial activities and pharmacokinetics of E-4767 and E-5065, two new 8-chlorofluoroquinolones with a 7-azetidin ring substituent. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11600365/),[μg] / [ml],0.007 to 0.5,110962,DB04576,Fleroxacin
,11600365,MICs,"The MICs of E-4767 and E-5065 at which 90% of the isolates tested were inhibited (MIC(90)s) were 0.007 to 0.5 microg/ml and 0.03 to 2 microg/ml, respectively, for gram-positive organisms and <or=0.003 to 0.06 microg/ml and 0.007 to 0.12 microg/ml, respectively, for members of the family Enterobacteriaceae except Serratia marcescens and Providencia spp. (MIC(90)s of E-4767 and E-5065 for these species were <or=0.5 microg/ml and <or=2 microg/ml, respectively).","Antibacterial activities and pharmacokinetics of E-4767 and E-5065, two new 8-chlorofluoroquinolones with a 7-azetidin ring substituent. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11600365/),[μg] / [ml],0.03 to 2,110963,DB04576,Fleroxacin
,11600365,MICs,"The MICs of E-4767 and E-5065 at which 90% of the isolates tested were inhibited (MIC(90)s) were 0.007 to 0.5 microg/ml and 0.03 to 2 microg/ml, respectively, for gram-positive organisms and <or=0.003 to 0.06 microg/ml and 0.007 to 0.12 microg/ml, respectively, for members of the family Enterobacteriaceae except Serratia marcescens and Providencia spp. (MIC(90)s of E-4767 and E-5065 for these species were <or=0.5 microg/ml and <or=2 microg/ml, respectively).","Antibacterial activities and pharmacokinetics of E-4767 and E-5065, two new 8-chlorofluoroquinolones with a 7-azetidin ring substituent. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11600365/),[μg] / [ml],0.007 to 0.12,110964,DB04576,Fleroxacin
,11600365,MIC(90)s,"The MICs of E-4767 and E-5065 at which 90% of the isolates tested were inhibited (MIC(90)s) were 0.007 to 0.5 microg/ml and 0.03 to 2 microg/ml, respectively, for gram-positive organisms and <or=0.003 to 0.06 microg/ml and 0.007 to 0.12 microg/ml, respectively, for members of the family Enterobacteriaceae except Serratia marcescens and Providencia spp. (MIC(90)s of E-4767 and E-5065 for these species were <or=0.5 microg/ml and <or=2 microg/ml, respectively).","Antibacterial activities and pharmacokinetics of E-4767 and E-5065, two new 8-chlorofluoroquinolones with a 7-azetidin ring substituent. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11600365/),[μg] / [ml],0.007 to 0.5,110965,DB04576,Fleroxacin
,11600365,MIC(90)s,"The MICs of E-4767 and E-5065 at which 90% of the isolates tested were inhibited (MIC(90)s) were 0.007 to 0.5 microg/ml and 0.03 to 2 microg/ml, respectively, for gram-positive organisms and <or=0.003 to 0.06 microg/ml and 0.007 to 0.12 microg/ml, respectively, for members of the family Enterobacteriaceae except Serratia marcescens and Providencia spp. (MIC(90)s of E-4767 and E-5065 for these species were <or=0.5 microg/ml and <or=2 microg/ml, respectively).","Antibacterial activities and pharmacokinetics of E-4767 and E-5065, two new 8-chlorofluoroquinolones with a 7-azetidin ring substituent. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11600365/),[μg] / [ml],0.03 to 2,110966,DB04576,Fleroxacin
<,11600365,MIC(90)s,"The MICs of E-4767 and E-5065 at which 90% of the isolates tested were inhibited (MIC(90)s) were 0.007 to 0.5 microg/ml and 0.03 to 2 microg/ml, respectively, for gram-positive organisms and <or=0.003 to 0.06 microg/ml and 0.007 to 0.12 microg/ml, respectively, for members of the family Enterobacteriaceae except Serratia marcescens and Providencia spp. (MIC(90)s of E-4767 and E-5065 for these species were <or=0.5 microg/ml and <or=2 microg/ml, respectively).","Antibacterial activities and pharmacokinetics of E-4767 and E-5065, two new 8-chlorofluoroquinolones with a 7-azetidin ring substituent. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11600365/),[μg] / [ml],0.003 to 0.06,110967,DB04576,Fleroxacin
,11600365,MIC(90)s,"The MICs of E-4767 and E-5065 at which 90% of the isolates tested were inhibited (MIC(90)s) were 0.007 to 0.5 microg/ml and 0.03 to 2 microg/ml, respectively, for gram-positive organisms and <or=0.003 to 0.06 microg/ml and 0.007 to 0.12 microg/ml, respectively, for members of the family Enterobacteriaceae except Serratia marcescens and Providencia spp. (MIC(90)s of E-4767 and E-5065 for these species were <or=0.5 microg/ml and <or=2 microg/ml, respectively).","Antibacterial activities and pharmacokinetics of E-4767 and E-5065, two new 8-chlorofluoroquinolones with a 7-azetidin ring substituent. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11600365/),[μg] / [ml],0.007 to 0.12,110968,DB04576,Fleroxacin
<,11600365,MIC(90)s,"The MICs of E-4767 and E-5065 at which 90% of the isolates tested were inhibited (MIC(90)s) were 0.007 to 0.5 microg/ml and 0.03 to 2 microg/ml, respectively, for gram-positive organisms and <or=0.003 to 0.06 microg/ml and 0.007 to 0.12 microg/ml, respectively, for members of the family Enterobacteriaceae except Serratia marcescens and Providencia spp. (MIC(90)s of E-4767 and E-5065 for these species were <or=0.5 microg/ml and <or=2 microg/ml, respectively).","Antibacterial activities and pharmacokinetics of E-4767 and E-5065, two new 8-chlorofluoroquinolones with a 7-azetidin ring substituent. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11600365/),[μg] / [ml],0.5,110969,DB04576,Fleroxacin
<,11600365,MIC(90)s,"The MICs of E-4767 and E-5065 at which 90% of the isolates tested were inhibited (MIC(90)s) were 0.007 to 0.5 microg/ml and 0.03 to 2 microg/ml, respectively, for gram-positive organisms and <or=0.003 to 0.06 microg/ml and 0.007 to 0.12 microg/ml, respectively, for members of the family Enterobacteriaceae except Serratia marcescens and Providencia spp. (MIC(90)s of E-4767 and E-5065 for these species were <or=0.5 microg/ml and <or=2 microg/ml, respectively).","Antibacterial activities and pharmacokinetics of E-4767 and E-5065, two new 8-chlorofluoroquinolones with a 7-azetidin ring substituent. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11600365/),[μg] / [ml],2,110970,DB04576,Fleroxacin
,11600365,MIC(90),For Pseudomonas aeruginosa both compounds had a MIC(90) of 0.5 microg/ml.,"Antibacterial activities and pharmacokinetics of E-4767 and E-5065, two new 8-chlorofluoroquinolones with a 7-azetidin ring substituent. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11600365/),[μg] / [ml],0.5,110971,DB04576,Fleroxacin
,11600365,MIC(90)s,"E-4767 and E-5065 were 356- and 32-fold more potent than ciprofloxacin against Bacteroides spp., and their MIC(90)s for Clostridium spp. were 0.25 and 0.5 microg/ml, respectively.","Antibacterial activities and pharmacokinetics of E-4767 and E-5065, two new 8-chlorofluoroquinolones with a 7-azetidin ring substituent. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11600365/),[μg] / [ml],0.25,110972,DB04576,Fleroxacin
,11600365,MIC(90)s,"E-4767 and E-5065 were 356- and 32-fold more potent than ciprofloxacin against Bacteroides spp., and their MIC(90)s for Clostridium spp. were 0.25 and 0.5 microg/ml, respectively.","Antibacterial activities and pharmacokinetics of E-4767 and E-5065, two new 8-chlorofluoroquinolones with a 7-azetidin ring substituent. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11600365/),[μg] / [ml],0.5,110973,DB04576,Fleroxacin
<or=,11600365,50% effective dose (ED(50)),"E-4767 was the most effective compound, with a 50% effective dose (ED(50)) of <or=17 mg/kg for all strains tested except ciprofloxacin-resistant S. aureus strains.","Antibacterial activities and pharmacokinetics of E-4767 and E-5065, two new 8-chlorofluoroquinolones with a 7-azetidin ring substituent. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11600365/),[mg] / [kg],17,110974,DB04576,Fleroxacin
<,11600365,ED(50),The ED(50) of E-4767 for these strains was <or=47.5 mg/kg.,"Antibacterial activities and pharmacokinetics of E-4767 and E-5065, two new 8-chlorofluoroquinolones with a 7-azetidin ring substituent. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11600365/),[mg] / [kg],47.5,110975,DB04576,Fleroxacin
,7726507,MICs,"The MICs of E-4695 at which 90% of the isolates were inhibited (MIC90s) were 0.06 to 0.5 microgram/ml for gram-positive cocci, including species of the genera Staphylococcus, Streptococcus, and Enterococcus, and the MIC90s against gram-negative pathogens such as members of the family Enterobacteriaceae (with the exception of Providencia spp. [MIC90, 8 micrograms/ml]) and Pseudomonas aeruginosa were 0.015 to 0.5 microgram/ml.","E-4695, a new C-7 azetidinyl fluoronaphthyridine with enhanced activity against gram-positive and anaerobic pathogens. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7726507/),[μg] / [ml],0.06 to 0.5,114945,DB04576,Fleroxacin
,7726507,MIC90,"The MICs of E-4695 at which 90% of the isolates were inhibited (MIC90s) were 0.06 to 0.5 microgram/ml for gram-positive cocci, including species of the genera Staphylococcus, Streptococcus, and Enterococcus, and the MIC90s against gram-negative pathogens such as members of the family Enterobacteriaceae (with the exception of Providencia spp. [MIC90, 8 micrograms/ml]) and Pseudomonas aeruginosa were 0.015 to 0.5 microgram/ml.","E-4695, a new C-7 azetidinyl fluoronaphthyridine with enhanced activity against gram-positive and anaerobic pathogens. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7726507/),[μg] / [ml],8,114946,DB04576,Fleroxacin
,7726507,MIC90,"The MICs of E-4695 at which 90% of the isolates were inhibited (MIC90s) were 0.06 to 0.5 microgram/ml for gram-positive cocci, including species of the genera Staphylococcus, Streptococcus, and Enterococcus, and the MIC90s against gram-negative pathogens such as members of the family Enterobacteriaceae (with the exception of Providencia spp. [MIC90, 8 micrograms/ml]) and Pseudomonas aeruginosa were 0.015 to 0.5 microgram/ml.","E-4695, a new C-7 azetidinyl fluoronaphthyridine with enhanced activity against gram-positive and anaerobic pathogens. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7726507/),[μg] / [ml],0.015 to 0.5,114947,DB04576,Fleroxacin
,7726507,maximum level,"After an oral dose of 50 mg/kg of body weight, the maximum level in serum, the biological half-life, and the area under the concentration-time curve from 0 to 10 h for E-4695 were 13.2 microgram/ml, 3.3 h, and 45.6 microgram .","E-4695, a new C-7 azetidinyl fluoronaphthyridine with enhanced activity against gram-positive and anaerobic pathogens. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7726507/),[μg] / [ml],13.2,114948,DB04576,Fleroxacin
,7726507,biological half-life,"After an oral dose of 50 mg/kg of body weight, the maximum level in serum, the biological half-life, and the area under the concentration-time curve from 0 to 10 h for E-4695 were 13.2 microgram/ml, 3.3 h, and 45.6 microgram .","E-4695, a new C-7 azetidinyl fluoronaphthyridine with enhanced activity against gram-positive and anaerobic pathogens. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7726507/),h,3.3,114949,DB04576,Fleroxacin
,7726507,area under the concentration-time curve from 0 to 10 h,"After an oral dose of 50 mg/kg of body weight, the maximum level in serum, the biological half-life, and the area under the concentration-time curve from 0 to 10 h for E-4695 were 13.2 microgram/ml, 3.3 h, and 45.6 microgram .","E-4695, a new C-7 azetidinyl fluoronaphthyridine with enhanced activity against gram-positive and anaerobic pathogens. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7726507/),μg,45.6,114950,DB04576,Fleroxacin
,7726507,area under the concentration-time curve from 0 to 4 h,The area under the concentration-time curve from 0 to 4 h for ciprofloxacin was 2.3 microgram .,"E-4695, a new C-7 azetidinyl fluoronaphthyridine with enhanced activity against gram-positive and anaerobic pathogens. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7726507/),μg,2.3,114951,DB04576,Fleroxacin
,7726507,Fifty-percent effective doses (ED50S),Fifty-percent effective doses (ED50S) against Staphylococcus aureus HS-93 infections in mice were 4.5 mg/kg with E-4695 and 37.6 mg/kg with ciprofloxacin.,"E-4695, a new C-7 azetidinyl fluoronaphthyridine with enhanced activity against gram-positive and anaerobic pathogens. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7726507/),[mg] / [kg],4.5,114952,DB04576,Fleroxacin
,7726507,Fifty-percent effective doses (ED50S),Fifty-percent effective doses (ED50S) against Staphylococcus aureus HS-93 infections in mice were 4.5 mg/kg with E-4695 and 37.6 mg/kg with ciprofloxacin.,"E-4695, a new C-7 azetidinyl fluoronaphthyridine with enhanced activity against gram-positive and anaerobic pathogens. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7726507/),[mg] / [kg],37.6,114953,DB04576,Fleroxacin
,7726507,ED50,"Infection with Streptococcus pneumoniae 29206 was more effectively treated with E-4695 (ED50, 41,2 mg/kg) than with ciprofloxacin (ED50, 200 mg/kg).","E-4695, a new C-7 azetidinyl fluoronaphthyridine with enhanced activity against gram-positive and anaerobic pathogens. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7726507/),[mg] / [kg],"41,2",114954,DB04576,Fleroxacin
,7726507,ED50,"Infection with Streptococcus pneumoniae 29206 was more effectively treated with E-4695 (ED50, 41,2 mg/kg) than with ciprofloxacin (ED50, 200 mg/kg).","E-4695, a new C-7 azetidinyl fluoronaphthyridine with enhanced activity against gram-positive and anaerobic pathogens. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7726507/),[mg] / [kg],200,114955,DB04576,Fleroxacin
,7726507,ED50,The ED50 of E-4695 for infections with Streptococcus pneumoniae 1625 was 132.2 mg/kg; ciprofloxacin was ineffective at 400 mg/kg against this strain.,"E-4695, a new C-7 azetidinyl fluoronaphthyridine with enhanced activity against gram-positive and anaerobic pathogens. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7726507/),[mg] / [kg],132.2,114956,DB04576,Fleroxacin
,7726507,ED50S,"E-4695 was also more potent than ciprofloxacin in treatment of infections caused by gram-negative organisms such as Escherichia coli HM-42 (ED50S, 1.0 and 3.9 mg/kg, respectively).","E-4695, a new C-7 azetidinyl fluoronaphthyridine with enhanced activity against gram-positive and anaerobic pathogens. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7726507/),[mg] / [kg],1.0,114957,DB04576,Fleroxacin
,7726507,ED50S,"E-4695 was also more potent than ciprofloxacin in treatment of infections caused by gram-negative organisms such as Escherichia coli HM-42 (ED50S, 1.0 and 3.9 mg/kg, respectively).","E-4695, a new C-7 azetidinyl fluoronaphthyridine with enhanced activity against gram-positive and anaerobic pathogens. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7726507/),[mg] / [kg],3.9,114958,DB04576,Fleroxacin
,7726507,ED50S,"The ED50S of E-4695 and ciprofloxacin were 33.0 and 145.5 mg/kg against P. aeruginosa HS-116 and 9.6 and 18.9 mg/kg against P. aeruginosa B-120, respectively.","E-4695, a new C-7 azetidinyl fluoronaphthyridine with enhanced activity against gram-positive and anaerobic pathogens. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7726507/),[mg] / [kg],33.0,114959,DB04576,Fleroxacin
,7726507,ED50S,"The ED50S of E-4695 and ciprofloxacin were 33.0 and 145.5 mg/kg against P. aeruginosa HS-116 and 9.6 and 18.9 mg/kg against P. aeruginosa B-120, respectively.","E-4695, a new C-7 azetidinyl fluoronaphthyridine with enhanced activity against gram-positive and anaerobic pathogens. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7726507/),[mg] / [kg],145.5,114960,DB04576,Fleroxacin
,7726507,ED50S,"The ED50S of E-4695 and ciprofloxacin were 33.0 and 145.5 mg/kg against P. aeruginosa HS-116 and 9.6 and 18.9 mg/kg against P. aeruginosa B-120, respectively.","E-4695, a new C-7 azetidinyl fluoronaphthyridine with enhanced activity against gram-positive and anaerobic pathogens. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7726507/),[mg] / [kg],9.6,114961,DB04576,Fleroxacin
,7726507,ED50S,"The ED50S of E-4695 and ciprofloxacin were 33.0 and 145.5 mg/kg against P. aeruginosa HS-116 and 9.6 and 18.9 mg/kg against P. aeruginosa B-120, respectively.","E-4695, a new C-7 azetidinyl fluoronaphthyridine with enhanced activity against gram-positive and anaerobic pathogens. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7726507/),[mg] / [kg],18.9,114962,DB04576,Fleroxacin
,17587989,MIC-90,"All the isolates were susceptible to the eight quinolones tested, with an MIC-90 ranging between 0.12 mg/L to 2.0 mg/L depending on the drug.",In vitro activity of eight fluoroquinolones against clinical isolates of Brucella melitensis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17587989/),[mg] / [l],0.12,126769,DB04576,Fleroxacin
,17587989,MIC-90,"All the isolates were susceptible to the eight quinolones tested, with an MIC-90 ranging between 0.12 mg/L to 2.0 mg/L depending on the drug.",In vitro activity of eight fluoroquinolones against clinical isolates of Brucella melitensis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17587989/),[mg] / [l],2.0,126770,DB04576,Fleroxacin
,2118328,Total,"Total theophylline clearance remained essentially unchanged throughout the study period (3.5 and 2.9 liters/h in the young and the elderly, respectively) both after a single fleroxacin dose and after multiple doses.",Safety of fleroxacin coadministered with theophylline to young and elderly volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2118328/),[l] / [h],3.5,128746,DB04576,Fleroxacin
,2118328,Total,"Total theophylline clearance remained essentially unchanged throughout the study period (3.5 and 2.9 liters/h in the young and the elderly, respectively) both after a single fleroxacin dose and after multiple doses.",Safety of fleroxacin coadministered with theophylline to young and elderly volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2118328/),[l] / [h],2.9,128747,DB04576,Fleroxacin
,2118328,clearance,"Total theophylline clearance remained essentially unchanged throughout the study period (3.5 and 2.9 liters/h in the young and the elderly, respectively) both after a single fleroxacin dose and after multiple doses.",Safety of fleroxacin coadministered with theophylline to young and elderly volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2118328/),[l] / [h],3.5,128748,DB04576,Fleroxacin
,2118328,clearance,"Total theophylline clearance remained essentially unchanged throughout the study period (3.5 and 2.9 liters/h in the young and the elderly, respectively) both after a single fleroxacin dose and after multiple doses.",Safety of fleroxacin coadministered with theophylline to young and elderly volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2118328/),[l] / [h],2.9,128749,DB04576,Fleroxacin
,3107959,Cmax,Characteristic of this new antibacterial are the high plasma levels following oral administration (Cmax: 4.5 micrograms/ml) and the long elimination half-lives (8-12 h).,A new trifluorinated quinolone: Ro 23-6240 (AM 833). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3107959/),[μg] / [ml],4.5,145646,DB04576,Fleroxacin
,3107959,elimination half-lives,Characteristic of this new antibacterial are the high plasma levels following oral administration (Cmax: 4.5 micrograms/ml) and the long elimination half-lives (8-12 h).,A new trifluorinated quinolone: Ro 23-6240 (AM 833). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3107959/),h,8-12,145647,DB04576,Fleroxacin
exceeds,3107959,volume of distribution at steady state,"In addition, the volume of distribution at steady state clearly exceeds 1 l/kg and points to good tissue penetration.",A new trifluorinated quinolone: Ro 23-6240 (AM 833). ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3107959/),[l] / [kg],1,145648,DB04576,Fleroxacin
,3107959,Total systemic clearance,Total systemic clearance was 122 ml/min and total renal clearance reached 89 ml/min.,A new trifluorinated quinolone: Ro 23-6240 (AM 833). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3107959/),[ml] / [min],122,145649,DB04576,Fleroxacin
,3107959,total renal clearance,Total systemic clearance was 122 ml/min and total renal clearance reached 89 ml/min.,A new trifluorinated quinolone: Ro 23-6240 (AM 833). ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3107959/),[ml] / [min],89,145650,DB04576,Fleroxacin
,3107959,absolute bioavailability,"The absolute bioavailability (extent of absorption) of the tablet amounted to 96%, indicating a complete absorption of this galenic formulation.",A new trifluorinated quinolone: Ro 23-6240 (AM 833). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3107959/),%,96,145651,DB04576,Fleroxacin
,1590696,maximum concentration,"The maximum concentration and the penetration into the aqueous and vitreous humors were 1.54 and 0.5 micrograms/ml and 27 and 10%, respectively.",Fleroxacin pharmacokinetics in aqueous and vitreous humors determined by using complete concentration-time data from individual rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1590696/),[μg] / [ml],1.54,149588,DB04576,Fleroxacin
,1590696,penetration,"The maximum concentration and the penetration into the aqueous and vitreous humors were 1.54 and 0.5 micrograms/ml and 27 and 10%, respectively.",Fleroxacin pharmacokinetics in aqueous and vitreous humors determined by using complete concentration-time data from individual rabbits. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1590696/),[μg] / [ml],0.5,149589,DB04576,Fleroxacin
,1590696,penetration,"The maximum concentration and the penetration into the aqueous and vitreous humors were 1.54 and 0.5 micrograms/ml and 27 and 10%, respectively.",Fleroxacin pharmacokinetics in aqueous and vitreous humors determined by using complete concentration-time data from individual rabbits. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1590696/),%,27,149590,DB04576,Fleroxacin
,1590696,penetration,"The maximum concentration and the penetration into the aqueous and vitreous humors were 1.54 and 0.5 micrograms/ml and 27 and 10%, respectively.",Fleroxacin pharmacokinetics in aqueous and vitreous humors determined by using complete concentration-time data from individual rabbits. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1590696/),%,10,149591,DB04576,Fleroxacin
,8842046,elimination clearance from the CSF,"The elimination clearance from the CSF for norfloxacin, AM-1155, fleroxacin, ofloxacin, sparfloxacin and pefloxacin was 14, 22, 21, 20, 47 and 35 microliters/min/rat, respectively.",Kinetics of quinolone antibiotics in rats: efflux from cerebrospinal fluid to the circulation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8842046/),[μl] / [min·rat],14,155385,DB04576,Fleroxacin
,8842046,elimination clearance from the CSF,"The elimination clearance from the CSF for norfloxacin, AM-1155, fleroxacin, ofloxacin, sparfloxacin and pefloxacin was 14, 22, 21, 20, 47 and 35 microliters/min/rat, respectively.",Kinetics of quinolone antibiotics in rats: efflux from cerebrospinal fluid to the circulation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8842046/),[μl] / [min·rat],22,155386,DB04576,Fleroxacin
,8842046,elimination clearance from the CSF,"The elimination clearance from the CSF for norfloxacin, AM-1155, fleroxacin, ofloxacin, sparfloxacin and pefloxacin was 14, 22, 21, 20, 47 and 35 microliters/min/rat, respectively.",Kinetics of quinolone antibiotics in rats: efflux from cerebrospinal fluid to the circulation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8842046/),[μl] / [min·rat],21,155387,DB04576,Fleroxacin
,8842046,elimination clearance from the CSF,"The elimination clearance from the CSF for norfloxacin, AM-1155, fleroxacin, ofloxacin, sparfloxacin and pefloxacin was 14, 22, 21, 20, 47 and 35 microliters/min/rat, respectively.",Kinetics of quinolone antibiotics in rats: efflux from cerebrospinal fluid to the circulation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8842046/),[μl] / [min·rat],20,155388,DB04576,Fleroxacin
,8842046,elimination clearance from the CSF,"The elimination clearance from the CSF for norfloxacin, AM-1155, fleroxacin, ofloxacin, sparfloxacin and pefloxacin was 14, 22, 21, 20, 47 and 35 microliters/min/rat, respectively.",Kinetics of quinolone antibiotics in rats: efflux from cerebrospinal fluid to the circulation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8842046/),[μl] / [min·rat],47,155389,DB04576,Fleroxacin
,8842046,elimination clearance from the CSF,"The elimination clearance from the CSF for norfloxacin, AM-1155, fleroxacin, ofloxacin, sparfloxacin and pefloxacin was 14, 22, 21, 20, 47 and 35 microliters/min/rat, respectively.",Kinetics of quinolone antibiotics in rats: efflux from cerebrospinal fluid to the circulation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8842046/),[μl] / [min·rat],35,155390,DB04576,Fleroxacin
,2116257,peak plasma concentration (Cmax),"The peak plasma concentration (Cmax) of fleroxacin was 15.6 +/- 1.6 mg/L, time to Cmax (tmax) was about 3h, elimination half-life (t1/2) was 16 +/- 1h and the percentage of unchanged fleroxacin excreted in urine was 39 +/- 3% of the dose.","Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in elderly patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2116257/),[mg] / [l],15.6,155721,DB04576,Fleroxacin
,2116257,time to Cmax (tmax),"The peak plasma concentration (Cmax) of fleroxacin was 15.6 +/- 1.6 mg/L, time to Cmax (tmax) was about 3h, elimination half-life (t1/2) was 16 +/- 1h and the percentage of unchanged fleroxacin excreted in urine was 39 +/- 3% of the dose.","Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in elderly patients. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2116257/),h,3,155722,DB04576,Fleroxacin
,2116257,elimination half-life (t1/2),"The peak plasma concentration (Cmax) of fleroxacin was 15.6 +/- 1.6 mg/L, time to Cmax (tmax) was about 3h, elimination half-life (t1/2) was 16 +/- 1h and the percentage of unchanged fleroxacin excreted in urine was 39 +/- 3% of the dose.","Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in elderly patients. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2116257/),h,16,155723,DB04576,Fleroxacin
,2116257,apparent volume of distribution (Vd/f),"Assuming that the bioavailability (f) is complete, the apparent volume of distribution (Vd/f) was lower in elderly (0.9 +/- 0.1 L/kg) than in younger patients (1.3 +/- 0.1 L/kg) and a 2-fold decrease in apparent total clearance (CL/f) was noted (2.58 +/- 0.42 vs 4.86 +/- 0.72 L/h); plasma concentrations were consequently higher in elderly patients.","Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in elderly patients. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2116257/),[l] / [kg],0.9,155724,DB04576,Fleroxacin
,2116257,apparent volume of distribution (Vd/f),"Assuming that the bioavailability (f) is complete, the apparent volume of distribution (Vd/f) was lower in elderly (0.9 +/- 0.1 L/kg) than in younger patients (1.3 +/- 0.1 L/kg) and a 2-fold decrease in apparent total clearance (CL/f) was noted (2.58 +/- 0.42 vs 4.86 +/- 0.72 L/h); plasma concentrations were consequently higher in elderly patients.","Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in elderly patients. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2116257/),[l] / [kg],1.3,155725,DB04576,Fleroxacin
,2116257,apparent total clearance (CL/f),"Assuming that the bioavailability (f) is complete, the apparent volume of distribution (Vd/f) was lower in elderly (0.9 +/- 0.1 L/kg) than in younger patients (1.3 +/- 0.1 L/kg) and a 2-fold decrease in apparent total clearance (CL/f) was noted (2.58 +/- 0.42 vs 4.86 +/- 0.72 L/h); plasma concentrations were consequently higher in elderly patients.","Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in elderly patients. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2116257/),[l] / [h],2.58,155726,DB04576,Fleroxacin
,2116257,apparent total clearance (CL/f),"Assuming that the bioavailability (f) is complete, the apparent volume of distribution (Vd/f) was lower in elderly (0.9 +/- 0.1 L/kg) than in younger patients (1.3 +/- 0.1 L/kg) and a 2-fold decrease in apparent total clearance (CL/f) was noted (2.58 +/- 0.42 vs 4.86 +/- 0.72 L/h); plasma concentrations were consequently higher in elderly patients.","Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in elderly patients. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2116257/),[l] / [h],4.86,155727,DB04576,Fleroxacin
,8843301,Di,Dialysis clearances (mean +/- standard deviation) calculated from the amount of drug recovered in the dialysate exceeded those calculated from rates of extraction from plasma for fleroxacin (126 +/- 29 versus 73 +/- 11 ml/min) and its metabolite N-demethylfleroxacin (103 +/- 31 versus 72 +/- 15 ml/min) but not that for the metabolite fleroxacin N-oxide (100 +/- 25 versus 100 +/- 12 ml/min).,Pharmacokinetics of fleroxacin after multiple oral dosing in patients receiving regular hemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8843301/),[ml] / [min],126,163923,DB04576,Fleroxacin
,8843301,Di,Dialysis clearances (mean +/- standard deviation) calculated from the amount of drug recovered in the dialysate exceeded those calculated from rates of extraction from plasma for fleroxacin (126 +/- 29 versus 73 +/- 11 ml/min) and its metabolite N-demethylfleroxacin (103 +/- 31 versus 72 +/- 15 ml/min) but not that for the metabolite fleroxacin N-oxide (100 +/- 25 versus 100 +/- 12 ml/min).,Pharmacokinetics of fleroxacin after multiple oral dosing in patients receiving regular hemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8843301/),[ml] / [min],100,163924,DB04576,Fleroxacin
,8843301,clearances,Dialysis clearances (mean +/- standard deviation) calculated from the amount of drug recovered in the dialysate exceeded those calculated from rates of extraction from plasma for fleroxacin (126 +/- 29 versus 73 +/- 11 ml/min) and its metabolite N-demethylfleroxacin (103 +/- 31 versus 72 +/- 15 ml/min) but not that for the metabolite fleroxacin N-oxide (100 +/- 25 versus 100 +/- 12 ml/min).,Pharmacokinetics of fleroxacin after multiple oral dosing in patients receiving regular hemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8843301/),[ml] / [min],126,163925,DB04576,Fleroxacin
,8843301,clearances,Dialysis clearances (mean +/- standard deviation) calculated from the amount of drug recovered in the dialysate exceeded those calculated from rates of extraction from plasma for fleroxacin (126 +/- 29 versus 73 +/- 11 ml/min) and its metabolite N-demethylfleroxacin (103 +/- 31 versus 72 +/- 15 ml/min) but not that for the metabolite fleroxacin N-oxide (100 +/- 25 versus 100 +/- 12 ml/min).,Pharmacokinetics of fleroxacin after multiple oral dosing in patients receiving regular hemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8843301/),[ml] / [min],73,163926,DB04576,Fleroxacin
,8843301,clearances,Dialysis clearances (mean +/- standard deviation) calculated from the amount of drug recovered in the dialysate exceeded those calculated from rates of extraction from plasma for fleroxacin (126 +/- 29 versus 73 +/- 11 ml/min) and its metabolite N-demethylfleroxacin (103 +/- 31 versus 72 +/- 15 ml/min) but not that for the metabolite fleroxacin N-oxide (100 +/- 25 versus 100 +/- 12 ml/min).,Pharmacokinetics of fleroxacin after multiple oral dosing in patients receiving regular hemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8843301/),[ml] / [min],103,163927,DB04576,Fleroxacin
,8843301,clearances,Dialysis clearances (mean +/- standard deviation) calculated from the amount of drug recovered in the dialysate exceeded those calculated from rates of extraction from plasma for fleroxacin (126 +/- 29 versus 73 +/- 11 ml/min) and its metabolite N-demethylfleroxacin (103 +/- 31 versus 72 +/- 15 ml/min) but not that for the metabolite fleroxacin N-oxide (100 +/- 25 versus 100 +/- 12 ml/min).,Pharmacokinetics of fleroxacin after multiple oral dosing in patients receiving regular hemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8843301/),[ml] / [min],72,163928,DB04576,Fleroxacin
,8843301,clearances,Dialysis clearances (mean +/- standard deviation) calculated from the amount of drug recovered in the dialysate exceeded those calculated from rates of extraction from plasma for fleroxacin (126 +/- 29 versus 73 +/- 11 ml/min) and its metabolite N-demethylfleroxacin (103 +/- 31 versus 72 +/- 15 ml/min) but not that for the metabolite fleroxacin N-oxide (100 +/- 25 versus 100 +/- 12 ml/min).,Pharmacokinetics of fleroxacin after multiple oral dosing in patients receiving regular hemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8843301/),[ml] / [min],100,163929,DB04576,Fleroxacin
,8843301,clearances,Dialysis clearances (mean +/- standard deviation) calculated from the amount of drug recovered in the dialysate exceeded those calculated from rates of extraction from plasma for fleroxacin (126 +/- 29 versus 73 +/- 11 ml/min) and its metabolite N-demethylfleroxacin (103 +/- 31 versus 72 +/- 15 ml/min) but not that for the metabolite fleroxacin N-oxide (100 +/- 25 versus 100 +/- 12 ml/min).,Pharmacokinetics of fleroxacin after multiple oral dosing in patients receiving regular hemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8843301/),[ml] / [min],100,163930,DB04576,Fleroxacin
,8843301,metabolic clearance,"The estimated metabolic clearance was 25 ml/min (coefficient of variation, 43%), and the calculated steady-state volume of distribution was 84 liters (coefficient of variation, 16%).",Pharmacokinetics of fleroxacin after multiple oral dosing in patients receiving regular hemodialysis. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8843301/),[ml] / [min],25,163931,DB04576,Fleroxacin
,8843301,steady-state volume of distribution,"The estimated metabolic clearance was 25 ml/min (coefficient of variation, 43%), and the calculated steady-state volume of distribution was 84 liters (coefficient of variation, 16%).",Pharmacokinetics of fleroxacin after multiple oral dosing in patients receiving regular hemodialysis. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8843301/),l,84,163932,DB04576,Fleroxacin
,8843301,Formation clearances,"Formation clearances of N-demethylfleroxacin and fleroxacin N-oxide were estimated to be 54 and 33% of fleroxacin's metabolic clearance, respectively.",Pharmacokinetics of fleroxacin after multiple oral dosing in patients receiving regular hemodialysis. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8843301/),%,54,163933,DB04576,Fleroxacin
,8843301,Formation clearances,"Formation clearances of N-demethylfleroxacin and fleroxacin N-oxide were estimated to be 54 and 33% of fleroxacin's metabolic clearance, respectively.",Pharmacokinetics of fleroxacin after multiple oral dosing in patients receiving regular hemodialysis. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8843301/),%,33,163934,DB04576,Fleroxacin
,18611628,peak concentrations,"Especially high peak concentrations (18 mug/g) were achieved in the kidney, liver, lung myocardium, and spleen.",Tissue pharmacokinetics of fleroxacin in humans as determined by positron emission tomography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18611628/),[μg] / [g],18,164509,DB04576,Fleroxacin
,18611628,plateau concentrations,"The mean plateau concentrations (2-8 h post-infusion, mug/g) were: brain 0.83; myocardium, 4.53; lung, 5.80, liver, 7.31; spleen, 6.00; bowel, 3.53; kidney, 8.85; bone, 2.87; muscle, 4.60; prostate, 4.65; uterus, 3.87; breast, 2.68; and blood, 2.35.",Tissue pharmacokinetics of fleroxacin in humans as determined by positron emission tomography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18611628/),[μg] / [g],0.83,164510,DB04576,Fleroxacin
,18611628,plateau concentrations,"The mean plateau concentrations (2-8 h post-infusion, mug/g) were: brain 0.83; myocardium, 4.53; lung, 5.80, liver, 7.31; spleen, 6.00; bowel, 3.53; kidney, 8.85; bone, 2.87; muscle, 4.60; prostate, 4.65; uterus, 3.87; breast, 2.68; and blood, 2.35.",Tissue pharmacokinetics of fleroxacin in humans as determined by positron emission tomography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18611628/),[μg] / [g],4.53,164511,DB04576,Fleroxacin
,18611628,plateau concentrations,"The mean plateau concentrations (2-8 h post-infusion, mug/g) were: brain 0.83; myocardium, 4.53; lung, 5.80, liver, 7.31; spleen, 6.00; bowel, 3.53; kidney, 8.85; bone, 2.87; muscle, 4.60; prostate, 4.65; uterus, 3.87; breast, 2.68; and blood, 2.35.",Tissue pharmacokinetics of fleroxacin in humans as determined by positron emission tomography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18611628/),[μg] / [g],5.80,164512,DB04576,Fleroxacin
,18611628,plateau concentrations,"The mean plateau concentrations (2-8 h post-infusion, mug/g) were: brain 0.83; myocardium, 4.53; lung, 5.80, liver, 7.31; spleen, 6.00; bowel, 3.53; kidney, 8.85; bone, 2.87; muscle, 4.60; prostate, 4.65; uterus, 3.87; breast, 2.68; and blood, 2.35.",Tissue pharmacokinetics of fleroxacin in humans as determined by positron emission tomography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18611628/),[μg] / [g],7.31,164513,DB04576,Fleroxacin
,18611628,plateau concentrations,"The mean plateau concentrations (2-8 h post-infusion, mug/g) were: brain 0.83; myocardium, 4.53; lung, 5.80, liver, 7.31; spleen, 6.00; bowel, 3.53; kidney, 8.85; bone, 2.87; muscle, 4.60; prostate, 4.65; uterus, 3.87; breast, 2.68; and blood, 2.35.",Tissue pharmacokinetics of fleroxacin in humans as determined by positron emission tomography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18611628/),[μg] / [g],6.00,164514,DB04576,Fleroxacin
,18611628,plateau concentrations,"The mean plateau concentrations (2-8 h post-infusion, mug/g) were: brain 0.83; myocardium, 4.53; lung, 5.80, liver, 7.31; spleen, 6.00; bowel, 3.53; kidney, 8.85; bone, 2.87; muscle, 4.60; prostate, 4.65; uterus, 3.87; breast, 2.68; and blood, 2.35.",Tissue pharmacokinetics of fleroxacin in humans as determined by positron emission tomography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18611628/),[μg] / [g],3.53,164515,DB04576,Fleroxacin
,18611628,plateau concentrations,"The mean plateau concentrations (2-8 h post-infusion, mug/g) were: brain 0.83; myocardium, 4.53; lung, 5.80, liver, 7.31; spleen, 6.00; bowel, 3.53; kidney, 8.85; bone, 2.87; muscle, 4.60; prostate, 4.65; uterus, 3.87; breast, 2.68; and blood, 2.35.",Tissue pharmacokinetics of fleroxacin in humans as determined by positron emission tomography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18611628/),[μg] / [g],8.85,164516,DB04576,Fleroxacin
,18611628,plateau concentrations,"The mean plateau concentrations (2-8 h post-infusion, mug/g) were: brain 0.83; myocardium, 4.53; lung, 5.80, liver, 7.31; spleen, 6.00; bowel, 3.53; kidney, 8.85; bone, 2.87; muscle, 4.60; prostate, 4.65; uterus, 3.87; breast, 2.68; and blood, 2.35.",Tissue pharmacokinetics of fleroxacin in humans as determined by positron emission tomography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18611628/),[μg] / [g],2.87,164517,DB04576,Fleroxacin
,18611628,plateau concentrations,"The mean plateau concentrations (2-8 h post-infusion, mug/g) were: brain 0.83; myocardium, 4.53; lung, 5.80, liver, 7.31; spleen, 6.00; bowel, 3.53; kidney, 8.85; bone, 2.87; muscle, 4.60; prostate, 4.65; uterus, 3.87; breast, 2.68; and blood, 2.35.",Tissue pharmacokinetics of fleroxacin in humans as determined by positron emission tomography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18611628/),[μg] / [g],4.60,164518,DB04576,Fleroxacin
,18611628,plateau concentrations,"The mean plateau concentrations (2-8 h post-infusion, mug/g) were: brain 0.83; myocardium, 4.53; lung, 5.80, liver, 7.31; spleen, 6.00; bowel, 3.53; kidney, 8.85; bone, 2.87; muscle, 4.60; prostate, 4.65; uterus, 3.87; breast, 2.68; and blood, 2.35.",Tissue pharmacokinetics of fleroxacin in humans as determined by positron emission tomography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18611628/),[μg] / [g],4.65,164519,DB04576,Fleroxacin
,18611628,plateau concentrations,"The mean plateau concentrations (2-8 h post-infusion, mug/g) were: brain 0.83; myocardium, 4.53; lung, 5.80, liver, 7.31; spleen, 6.00; bowel, 3.53; kidney, 8.85; bone, 2.87; muscle, 4.60; prostate, 4.65; uterus, 3.87; breast, 2.68; and blood, 2.35.",Tissue pharmacokinetics of fleroxacin in humans as determined by positron emission tomography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18611628/),[μg] / [g],3.87,164520,DB04576,Fleroxacin
,18611628,plateau concentrations,"The mean plateau concentrations (2-8 h post-infusion, mug/g) were: brain 0.83; myocardium, 4.53; lung, 5.80, liver, 7.31; spleen, 6.00; bowel, 3.53; kidney, 8.85; bone, 2.87; muscle, 4.60; prostate, 4.65; uterus, 3.87; breast, 2.68; and blood, 2.35.",Tissue pharmacokinetics of fleroxacin in humans as determined by positron emission tomography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18611628/),[μg] / [g],2,164521,DB04576,Fleroxacin
,18611628,plateau concentrations,"The mean plateau concentrations (2-8 h post-infusion, mug/g) were: brain 0.83; myocardium, 4.53; lung, 5.80, liver, 7.31; spleen, 6.00; bowel, 3.53; kidney, 8.85; bone, 2.87; muscle, 4.60; prostate, 4.65; uterus, 3.87; breast, 2.68; and blood, 2.35.",Tissue pharmacokinetics of fleroxacin in humans as determined by positron emission tomography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18611628/),[μg] / [g],2.35,164522,DB04576,Fleroxacin
<,18611628,MIC(90)'s,"Since the MIC(90)'s of the family Enterobacterioaceae and Neisseria gonorrhoeae are <2 mug/ml, with the great majority of the individual species 1 mug/ml, these results suggest that a single daily dose of 400 mg of fleroxacin should be effective in the treatment of infections such as urinary tract infection and gonorrhea.",Tissue pharmacokinetics of fleroxacin in humans as determined by positron emission tomography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18611628/),[μg] / [ml],2,164523,DB04576,Fleroxacin
,18611628,MIC(90)'s,"Since the MIC(90)'s of the family Enterobacterioaceae and Neisseria gonorrhoeae are <2 mug/ml, with the great majority of the individual species 1 mug/ml, these results suggest that a single daily dose of 400 mg of fleroxacin should be effective in the treatment of infections such as urinary tract infection and gonorrhea.",Tissue pharmacokinetics of fleroxacin in humans as determined by positron emission tomography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18611628/),[μg] / [ml],1,164524,DB04576,Fleroxacin
,8851573,CL/F,"The predicted CL/F and V/F were 83.5 ml/min and 101 liters, respectively, for a typical male subject (CLCR, 70 ml/min; LBW, 54 kg; age, 54 years).",Factors influencing elimination and distribution of fleroxacin: metaanalysis of individual data from 10 pharmacokinetic studies. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851573/),[ml] / [min],83.5,164576,DB04576,Fleroxacin
,8851573,V/F,"The predicted CL/F and V/F were 83.5 ml/min and 101 liters, respectively, for a typical male subject (CLCR, 70 ml/min; LBW, 54 kg; age, 54 years).",Factors influencing elimination and distribution of fleroxacin: metaanalysis of individual data from 10 pharmacokinetic studies. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851573/),l,101,164577,DB04576,Fleroxacin
,8851573,V/F,V/F was found to be 20.4 liters greater in males than in females.,Factors influencing elimination and distribution of fleroxacin: metaanalysis of individual data from 10 pharmacokinetic studies. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851573/),l,20.4,164578,DB04576,Fleroxacin
>,8452185,steady-state volume of distribution (Vd-ss,"Renal impairment had no influence on the complete absorption of fleroxacin from the gastrointestinal tract, the maximal plasma concentration, and the steady-state volume of distribution (Vd-ss > 1 L/kg).",Pharmacokinetics of fleroxacin in renal impairment. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8452185/),[l] / [kg],1,165994,DB04576,Fleroxacin
,8452185,systemic clearance,"However, systemic clearance in patients was significantly decreased (p < 0.05) to 44.4 mL/min compared with 87.1 mL/min in healthy subjects.",Pharmacokinetics of fleroxacin in renal impairment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8452185/),[ml] / [min],44.4,165995,DB04576,Fleroxacin
,8452185,systemic clearance,"However, systemic clearance in patients was significantly decreased (p < 0.05) to 44.4 mL/min compared with 87.1 mL/min in healthy subjects.",Pharmacokinetics of fleroxacin in renal impairment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8452185/),[ml] / [min],87.1,165996,DB04576,Fleroxacin
,8452185,renal clearance,This decrease could be ascribed to a reduction in renal clearance from 59.1 mL/min in healthy subjects to 8.8 mL/min in patients.,Pharmacokinetics of fleroxacin in renal impairment. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8452185/),[ml] / [min],59.1,165997,DB04576,Fleroxacin
,8452185,renal clearance,This decrease could be ascribed to a reduction in renal clearance from 59.1 mL/min in healthy subjects to 8.8 mL/min in patients.,Pharmacokinetics of fleroxacin in renal impairment. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8452185/),[ml] / [min],8.8,165998,DB04576,Fleroxacin
,8452185,elimination half-life,"As a consequence of reduced clearance, the mean elimination half-life in patients increased from 13.6 hours to 21.4 hours and the area under the concentration-time curve from 87.0 mg.h/L to 170.5 mg.h/L.",Pharmacokinetics of fleroxacin in renal impairment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8452185/),h,13.6,165999,DB04576,Fleroxacin
,8452185,elimination half-life,"As a consequence of reduced clearance, the mean elimination half-life in patients increased from 13.6 hours to 21.4 hours and the area under the concentration-time curve from 87.0 mg.h/L to 170.5 mg.h/L.",Pharmacokinetics of fleroxacin in renal impairment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8452185/),h,21.4,166000,DB04576,Fleroxacin
,8452185,area under the concentration-time curve,"As a consequence of reduced clearance, the mean elimination half-life in patients increased from 13.6 hours to 21.4 hours and the area under the concentration-time curve from 87.0 mg.h/L to 170.5 mg.h/L.",Pharmacokinetics of fleroxacin in renal impairment. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8452185/),[h·mg] / [l],87.0,166001,DB04576,Fleroxacin
,8452185,area under the concentration-time curve,"As a consequence of reduced clearance, the mean elimination half-life in patients increased from 13.6 hours to 21.4 hours and the area under the concentration-time curve from 87.0 mg.h/L to 170.5 mg.h/L.",Pharmacokinetics of fleroxacin in renal impairment. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8452185/),[h·mg] / [l],170.5,166002,DB04576,Fleroxacin
,2542469,Metabolism,Metabolism is minimal (ca. 15-20% for ciprofloxacin and norfloxacin).,Pharmacokinetics of ciprofloxacin with reference to other fluorinated quinolones. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2542469/),%,15-20,166231,DB04576,Fleroxacin
,2542469,serum half-life,"Because the transintestinal route of elimination compensates for loss of renal elimination, the serum half-life of ciprofloxacvin is raised only to 5-10 hours even in total renal failure.",Pharmacokinetics of ciprofloxacin with reference to other fluorinated quinolones. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2542469/),h,5-10,166232,DB04576,Fleroxacin
,3094441,Elimination half-lives,"Elimination half-lives in serum were species dependent, ranging from 1.57 h in rabbits to 9.42 h in dogs.","Pharmacokinetics of a new quinolone, AM-833, in mice, rats, rabbits, dogs, and monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3094441/),h,1.57,172049,DB04576,Fleroxacin
,3094441,Elimination half-lives,"Elimination half-lives in serum were species dependent, ranging from 1.57 h in rabbits to 9.42 h in dogs.","Pharmacokinetics of a new quinolone, AM-833, in mice, rats, rabbits, dogs, and monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3094441/),h,9.42,172050,DB04576,Fleroxacin
,2509509,signal-to-noise ratio,"At a signal-to-noise ratio of 4, the detection limits in serum are 2.5, 10 and 20 ng/ml, for fleroxacin, temafloxacin and A-64730, respectively.","High-performance liquid chromatography for the determination of three new fluoroquinolones, fleroxacin, temafloxacin and A-64730, in biological fluids. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2509509/),[ng] / [ml],4,174056,DB04576,Fleroxacin
,2509509,detection limits,"At a signal-to-noise ratio of 4, the detection limits in serum are 2.5, 10 and 20 ng/ml, for fleroxacin, temafloxacin and A-64730, respectively.","High-performance liquid chromatography for the determination of three new fluoroquinolones, fleroxacin, temafloxacin and A-64730, in biological fluids. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2509509/),[ng] / [ml],4,174057,DB04576,Fleroxacin
,2509509,detection limits,"At a signal-to-noise ratio of 4, the detection limits in serum are 2.5, 10 and 20 ng/ml, for fleroxacin, temafloxacin and A-64730, respectively.","High-performance liquid chromatography for the determination of three new fluoroquinolones, fleroxacin, temafloxacin and A-64730, in biological fluids. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2509509/),[ng] / [ml],2.5,174058,DB04576,Fleroxacin
,2509509,detection limits,"At a signal-to-noise ratio of 4, the detection limits in serum are 2.5, 10 and 20 ng/ml, for fleroxacin, temafloxacin and A-64730, respectively.","High-performance liquid chromatography for the determination of three new fluoroquinolones, fleroxacin, temafloxacin and A-64730, in biological fluids. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2509509/),[ng] / [ml],10,174059,DB04576,Fleroxacin
,2509509,detection limits,"At a signal-to-noise ratio of 4, the detection limits in serum are 2.5, 10 and 20 ng/ml, for fleroxacin, temafloxacin and A-64730, respectively.","High-performance liquid chromatography for the determination of three new fluoroquinolones, fleroxacin, temafloxacin and A-64730, in biological fluids. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2509509/),[ng] / [ml],20,174060,DB04576,Fleroxacin
,9458187,Peak plasma concentrations,Peak plasma concentrations of ofloxacin in adult rats were 20.5 +/- 5.6 mg/l (mean +/- SD) following treatment with a single dose of 600 mg/kg body wt.,"Quinolone-induced arthropathy: exposure of magnesium-deficient aged rats or immature rats, mineral concentrations in target tissues and pharmacokinetics. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9458187/),[mg] / [l],20.5,183940,DB04576,Fleroxacin
,3144537,urinary recovery,"The urinary recovery of fleroxacin was 49.5% over 72 h; the N-demethyl and N-oxide metabolites accounted for 6.9% and 5.7%, respectively, of the administered dose.",The metabolism and pharmacokinetics of fleroxacin in healthy subjects. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3144537/),%,49.5,186324,DB04576,Fleroxacin
,3144537,urinary recovery,"The urinary recovery of fleroxacin was 49.5% over 72 h; the N-demethyl and N-oxide metabolites accounted for 6.9% and 5.7%, respectively, of the administered dose.",The metabolism and pharmacokinetics of fleroxacin in healthy subjects. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3144537/),%,6.9,186325,DB04576,Fleroxacin
,3144537,urinary recovery,"The urinary recovery of fleroxacin was 49.5% over 72 h; the N-demethyl and N-oxide metabolites accounted for 6.9% and 5.7%, respectively, of the administered dose.",The metabolism and pharmacokinetics of fleroxacin in healthy subjects. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3144537/),%,5.7,186326,DB04576,Fleroxacin
,1482143,relative bioavailability,"The relative bioavailability of fleroxacin given with sucralfate, calculated from the area under the concentration-time curve, was 76% compared with that of fleroxacin alone.",Effect of sucralfate on pharmacokinetics of fleroxacin in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1482143/),%,76,194657,DB04576,Fleroxacin
,1482143,bioavailabilities,This is significantly better than the bioavailabilities of other quinolones (1.8 to 12.3%) when they are administered with sucralfate.,Effect of sucralfate on pharmacokinetics of fleroxacin in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1482143/),%,1.8 to 12.3,194658,DB04576,Fleroxacin
,18611635,serum half-life,Its long serum half-life (8-12 h) allows once-a-day dosing.,Implications of fleroxacin's pharmacokinetic profile. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18611635/),h,8-12,196724,DB04576,Fleroxacin
,2920479,bioavailability,"Absorption of norfloxacin, ciprofloxacin, and enoxacin is incomplete, whereas the bioavailability of pefloxacin, ofloxacin and fleroxacin is almost 100%.",The pharmacokinetics and tissue penetration of the fluoroquinolones. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2920479/),%,100,197116,DB04576,Fleroxacin
,2920479,Maximum serum concentrations,Maximum serum concentrations vary between 1.5 and 10.7 micrograms/ml depending on the dose and antibiotic given.,The pharmacokinetics and tissue penetration of the fluoroquinolones. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2920479/),[μg] / [ml],1.5,197117,DB04576,Fleroxacin
,2920479,Maximum serum concentrations,Maximum serum concentrations vary between 1.5 and 10.7 micrograms/ml depending on the dose and antibiotic given.,The pharmacokinetics and tissue penetration of the fluoroquinolones. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2920479/),[μg] / [ml],10.7,197118,DB04576,Fleroxacin
,2920479,AUC's,Respective AUC's of 78 and 5.5 micrograms/ml-h are observed following the administration of 400 mg of either fleroxacin or norfloxacin.,The pharmacokinetics and tissue penetration of the fluoroquinolones. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2920479/),[μg] / [ml-h],78,197119,DB04576,Fleroxacin
,2920479,AUC's,Respective AUC's of 78 and 5.5 micrograms/ml-h are observed following the administration of 400 mg of either fleroxacin or norfloxacin.,The pharmacokinetics and tissue penetration of the fluoroquinolones. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2920479/),[μg] / [ml-h],5.5,197120,DB04576,Fleroxacin
,2920479,apparent volume of distribution,Protein binding is low (less than or equal to 30%) and apparent volume of distribution is between 1.5 and 3.1 liters/kg.,The pharmacokinetics and tissue penetration of the fluoroquinolones. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2920479/),[l] / [kg],1.5 and 3.1,197121,DB04576,Fleroxacin
,2920479,half-lives,"Norfloxacin and ciprofloxacin have the shortest half-lives (+/- 4h), while fleroxacin and pefloxacin have the longest (10-12h).",The pharmacokinetics and tissue penetration of the fluoroquinolones. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2920479/),h,10-12,197122,DB04576,Fleroxacin
,8452186,maximal plasma concentrations,"After administration of the standard dose of 400 mg once daily, the maximal plasma concentrations were 5-7 mg/L at steady-state and the minimal concentrations were approximately 1 mg/L at the end of the dosing interval.",Penetration of fleroxacin into body tissues and fluids. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8452186/),[mg] / [l],5-7,199192,DB04576,Fleroxacin
,8452186,minimal concentrations,"After administration of the standard dose of 400 mg once daily, the maximal plasma concentrations were 5-7 mg/L at steady-state and the minimal concentrations were approximately 1 mg/L at the end of the dosing interval.",Penetration of fleroxacin into body tissues and fluids. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8452186/),[mg] / [l],1,199193,DB04576,Fleroxacin
,2113797,maximum concentration,"The maximum concentration in serum and the time to achieve that maximum were 6.2 +/- 2.2 micrograms/ml and 0.94 +/- 0.62 h, respectively.",Steady-state pharmacokinetics of fleroxacin in patients with skin and skin structure infections. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2113797/),[μg] / [ml],6.2,202388,DB04576,Fleroxacin
,2113797,time to achieve that maximum,"The maximum concentration in serum and the time to achieve that maximum were 6.2 +/- 2.2 micrograms/ml and 0.94 +/- 0.62 h, respectively.",Steady-state pharmacokinetics of fleroxacin in patients with skin and skin structure infections. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2113797/),h,0.94,202389,DB04576,Fleroxacin
,2113797,absorption half-life,"The absorption half-life, alpha half-life, beta half-life, apparent steady-state volume of distribution, apparent total body clearance, and renal clearance were 0.56 +/- 0.37 h, 0.78 +/- 0.51 h, 10.56 +/- 1.40 h, 0.85 +/- 0.31 liters/kg, 129.2 +/- 19.6 ml/min, and 53.3 +/- 16.7 ml/min, respectively.",Steady-state pharmacokinetics of fleroxacin in patients with skin and skin structure infections. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2113797/),h,0.56,202390,DB04576,Fleroxacin
,2113797,renal clearance,"The absorption half-life, alpha half-life, beta half-life, apparent steady-state volume of distribution, apparent total body clearance, and renal clearance were 0.56 +/- 0.37 h, 0.78 +/- 0.51 h, 10.56 +/- 1.40 h, 0.85 +/- 0.31 liters/kg, 129.2 +/- 19.6 ml/min, and 53.3 +/- 16.7 ml/min, respectively.",Steady-state pharmacokinetics of fleroxacin in patients with skin and skin structure infections. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2113797/),[ml] / [min],53.3,202391,DB04576,Fleroxacin
,2116256,Cmax,"In healthy subjects, Cmax was 6.8 +/- 0.7 mg/L; tmax = about 1h, t1/2 = 14 +/- 2h, total clearance = 4.86 +/- 0.72 L/h and the percentage of unchanged fleroxacin excreted in urine in 48 hours was 48 +/- 4% (HPLC).","Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in renal failure and influence of haemodialysis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2116256/),[mg] / [l],6.8,209034,DB04576,Fleroxacin
,2116256,tmax,"In healthy subjects, Cmax was 6.8 +/- 0.7 mg/L; tmax = about 1h, t1/2 = 14 +/- 2h, total clearance = 4.86 +/- 0.72 L/h and the percentage of unchanged fleroxacin excreted in urine in 48 hours was 48 +/- 4% (HPLC).","Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in renal failure and influence of haemodialysis. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2116256/),h,1,209035,DB04576,Fleroxacin
,2116256,t1/2,"In healthy subjects, Cmax was 6.8 +/- 0.7 mg/L; tmax = about 1h, t1/2 = 14 +/- 2h, total clearance = 4.86 +/- 0.72 L/h and the percentage of unchanged fleroxacin excreted in urine in 48 hours was 48 +/- 4% (HPLC).","Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in renal failure and influence of haemodialysis. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2116256/),h,14,209036,DB04576,Fleroxacin
,2116256,total clearance,"In healthy subjects, Cmax was 6.8 +/- 0.7 mg/L; tmax = about 1h, t1/2 = 14 +/- 2h, total clearance = 4.86 +/- 0.72 L/h and the percentage of unchanged fleroxacin excreted in urine in 48 hours was 48 +/- 4% (HPLC).","Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in renal failure and influence of haemodialysis. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2116256/),[l] / [h],4.86,209037,DB04576,Fleroxacin
,2116256,Dialysance,Dialysance of fleroxacin and of its metabolites was approximately 3.6 to 4.8 L/h.,"Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in renal failure and influence of haemodialysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2116256/),[l] / [h],3.6 to 4.8,209038,DB04576,Fleroxacin
exceeded,1622175,volume of distribution,The volume of distribution exceeded 1 liter/kg in healthy controls and was not affected by liver impairment (P greater than 0.05).,Fleroxacin pharmacokinetics in patients with liver cirrhosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1622175/),[l] / [kg],1,214595,DB04576,Fleroxacin
,8851589,Plateau concentrations,"Plateau concentrations (2 to 8 h; given as mean micrograms per gram +/- standard error of the mean) of drug in kidneys (15.11 +/- 0.55), prostate glands (5.08 +/- 0.19), and lungs (5.75 +/- 0.22) were also well above the MIC90 for most relevant pathogens.",Pharmacokinetics of [18F]fleroxacin in patients with acute exacerbations of chronic bronchitis and complicated urinary tract infection studied by positron emission tomography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851589/),,15.11,216408,DB04576,Fleroxacin
,8851589,Plateau concentrations,"Plateau concentrations (2 to 8 h; given as mean micrograms per gram +/- standard error of the mean) of drug in kidneys (15.11 +/- 0.55), prostate glands (5.08 +/- 0.19), and lungs (5.75 +/- 0.22) were also well above the MIC90 for most relevant pathogens.",Pharmacokinetics of [18F]fleroxacin in patients with acute exacerbations of chronic bronchitis and complicated urinary tract infection studied by positron emission tomography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851589/),,5.08,216409,DB04576,Fleroxacin
,8851589,Plateau concentrations,"Plateau concentrations (2 to 8 h; given as mean micrograms per gram +/- standard error of the mean) of drug in kidneys (15.11 +/- 0.55), prostate glands (5.08 +/- 0.19), and lungs (5.75 +/- 0.22) were also well above the MIC90 for most relevant pathogens.",Pharmacokinetics of [18F]fleroxacin in patients with acute exacerbations of chronic bronchitis and complicated urinary tract infection studied by positron emission tomography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851589/),,5.75,216410,DB04576,Fleroxacin
,2128442,peak concentration,The mean (+/- the standard deviation) peak concentration in plasma was 8.2 +/- 4.0 mg/liter at 8.3 h.,Pharmacokinetics and biliary concentrations of fleroxacin in cholecystectomized patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2128442/),[mg] / [l],8.2,227286,DB04576,Fleroxacin
,2128442,elimination half-life,"The harmonic mean elimination half-life was 10.5 h, which is comparable to that reported for healthy volunteers.",Pharmacokinetics and biliary concentrations of fleroxacin in cholecystectomized patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2128442/),h,10.5,227287,DB04576,Fleroxacin
,2128442,renal clearance,"This increase resulted from reduced renal clearance (mean [+/- standard deviation], 38 +/- 22 ml/min), as the volume of distribution in the patients (1.4 +/- 0.7 liter/kg) did not differ from that reported for healthy subjects.",Pharmacokinetics and biliary concentrations of fleroxacin in cholecystectomized patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2128442/),[ml] / [min],38,227288,DB04576,Fleroxacin
,2128442,volume of distribution,"This increase resulted from reduced renal clearance (mean [+/- standard deviation], 38 +/- 22 ml/min), as the volume of distribution in the patients (1.4 +/- 0.7 liter/kg) did not differ from that reported for healthy subjects.",Pharmacokinetics and biliary concentrations of fleroxacin in cholecystectomized patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2128442/),[l] / [kg],1.4,227289,DB04576,Fleroxacin
,2128442,Maximum concentrations,"Maximum concentrations in T-drain bile were high (median, 22.1 mg/liter) and exceeded those measured in plasma by a factor of 2 to 3; the individual ratios of the area under the curve for bile divided by that for plasma ranged from 1.3 to 9.9.",Pharmacokinetics and biliary concentrations of fleroxacin in cholecystectomized patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2128442/),[mg] / [l],22.1,227290,DB04576,Fleroxacin
<,1444310,MICs,"Since the MICs for 90% of all Enterobacteriaceae are <2 micrograms/ml, fleroxacin should be particularly useful in treating gram-negative infections affecting these tissues.","Pharmacokinetics of 18F-labeled fleroxacin in rabbits with Escherichia coli infections, studied with positron emission tomography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1444310/),[μg] / [ml],2,229014,DB04576,Fleroxacin
less,2808194,MICs,"The MICs of temafloxacin for 90% of Haemophilus influenzae, Neisseria spp., Enterobacteriaceae, Bacteroides fragilis and Ch. trachomatis were all less than or equal to 1 mg/l, an activity comparable with or superior to that of ofloxacin and superior to those of fleroxacin and norfloxacin.","The in-vitro activity, pharmacokinetics and tissue penetration of temafloxacin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2808194/),[mg] / [l],1,229876,DB04576,Fleroxacin
,2808194,peak plasma levels,Mean peak plasma levels of 3.3 mg/l were achieved.,"The in-vitro activity, pharmacokinetics and tissue penetration of temafloxacin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2808194/),[mg] / [l],3.3,229877,DB04576,Fleroxacin
,2808194,plasma elimination half life,The mean plasma elimination half life was 6.8 h and the percentage penetration into blister fluid was 104.5%.,"The in-vitro activity, pharmacokinetics and tissue penetration of temafloxacin. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2808194/),h,6.8,229878,DB04576,Fleroxacin
,2808194,percentage penetration into blister fluid,The mean plasma elimination half life was 6.8 h and the percentage penetration into blister fluid was 104.5%.,"The in-vitro activity, pharmacokinetics and tissue penetration of temafloxacin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2808194/),%,104.5,229879,DB04576,Fleroxacin
,8257137,plateau concentrations,"The plateau concentrations in tissues (2 to 8 h, in micrograms per gram +/- standard error of the mean) of drug were as follows: brain, 0.83 +/- 0.032; myocardium, 4.53 +/- 0.24; lung, 5.80 +/- 0.48; liver, 7.31 +/- 0.33; spleen, 6.00 +/- 0.47; bowel, 3.53 +/- 0.74; kidney, 8.85 +/- 0.64; bone, 2.87 +/- 0.29; muscle, 4.60 +/- 0.33; prostate, 4.65 +/- 0.48; uterus, 3.87 +/- 0.39; breast, 2.68 +/- 0.11; and blood, 2.35 +/- 0.09.",Pharmacokinetics of [18F]fleroxacin in healthy human subjects studied by using positron emission tomography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257137/),,0.83,238048,DB04576,Fleroxacin
,8257137,plateau concentrations,"The plateau concentrations in tissues (2 to 8 h, in micrograms per gram +/- standard error of the mean) of drug were as follows: brain, 0.83 +/- 0.032; myocardium, 4.53 +/- 0.24; lung, 5.80 +/- 0.48; liver, 7.31 +/- 0.33; spleen, 6.00 +/- 0.47; bowel, 3.53 +/- 0.74; kidney, 8.85 +/- 0.64; bone, 2.87 +/- 0.29; muscle, 4.60 +/- 0.33; prostate, 4.65 +/- 0.48; uterus, 3.87 +/- 0.39; breast, 2.68 +/- 0.11; and blood, 2.35 +/- 0.09.",Pharmacokinetics of [18F]fleroxacin in healthy human subjects studied by using positron emission tomography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257137/),,4.53,238049,DB04576,Fleroxacin
,8257137,plateau concentrations,"The plateau concentrations in tissues (2 to 8 h, in micrograms per gram +/- standard error of the mean) of drug were as follows: brain, 0.83 +/- 0.032; myocardium, 4.53 +/- 0.24; lung, 5.80 +/- 0.48; liver, 7.31 +/- 0.33; spleen, 6.00 +/- 0.47; bowel, 3.53 +/- 0.74; kidney, 8.85 +/- 0.64; bone, 2.87 +/- 0.29; muscle, 4.60 +/- 0.33; prostate, 4.65 +/- 0.48; uterus, 3.87 +/- 0.39; breast, 2.68 +/- 0.11; and blood, 2.35 +/- 0.09.",Pharmacokinetics of [18F]fleroxacin in healthy human subjects studied by using positron emission tomography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257137/),,5.80,238050,DB04576,Fleroxacin
,8257137,plateau concentrations,"The plateau concentrations in tissues (2 to 8 h, in micrograms per gram +/- standard error of the mean) of drug were as follows: brain, 0.83 +/- 0.032; myocardium, 4.53 +/- 0.24; lung, 5.80 +/- 0.48; liver, 7.31 +/- 0.33; spleen, 6.00 +/- 0.47; bowel, 3.53 +/- 0.74; kidney, 8.85 +/- 0.64; bone, 2.87 +/- 0.29; muscle, 4.60 +/- 0.33; prostate, 4.65 +/- 0.48; uterus, 3.87 +/- 0.39; breast, 2.68 +/- 0.11; and blood, 2.35 +/- 0.09.",Pharmacokinetics of [18F]fleroxacin in healthy human subjects studied by using positron emission tomography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257137/),,7.31,238051,DB04576,Fleroxacin
,8257137,plateau concentrations,"The plateau concentrations in tissues (2 to 8 h, in micrograms per gram +/- standard error of the mean) of drug were as follows: brain, 0.83 +/- 0.032; myocardium, 4.53 +/- 0.24; lung, 5.80 +/- 0.48; liver, 7.31 +/- 0.33; spleen, 6.00 +/- 0.47; bowel, 3.53 +/- 0.74; kidney, 8.85 +/- 0.64; bone, 2.87 +/- 0.29; muscle, 4.60 +/- 0.33; prostate, 4.65 +/- 0.48; uterus, 3.87 +/- 0.39; breast, 2.68 +/- 0.11; and blood, 2.35 +/- 0.09.",Pharmacokinetics of [18F]fleroxacin in healthy human subjects studied by using positron emission tomography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257137/),,6.00,238052,DB04576,Fleroxacin
,8257137,plateau concentrations,"The plateau concentrations in tissues (2 to 8 h, in micrograms per gram +/- standard error of the mean) of drug were as follows: brain, 0.83 +/- 0.032; myocardium, 4.53 +/- 0.24; lung, 5.80 +/- 0.48; liver, 7.31 +/- 0.33; spleen, 6.00 +/- 0.47; bowel, 3.53 +/- 0.74; kidney, 8.85 +/- 0.64; bone, 2.87 +/- 0.29; muscle, 4.60 +/- 0.33; prostate, 4.65 +/- 0.48; uterus, 3.87 +/- 0.39; breast, 2.68 +/- 0.11; and blood, 2.35 +/- 0.09.",Pharmacokinetics of [18F]fleroxacin in healthy human subjects studied by using positron emission tomography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257137/),,3.53,238053,DB04576,Fleroxacin
,8257137,plateau concentrations,"The plateau concentrations in tissues (2 to 8 h, in micrograms per gram +/- standard error of the mean) of drug were as follows: brain, 0.83 +/- 0.032; myocardium, 4.53 +/- 0.24; lung, 5.80 +/- 0.48; liver, 7.31 +/- 0.33; spleen, 6.00 +/- 0.47; bowel, 3.53 +/- 0.74; kidney, 8.85 +/- 0.64; bone, 2.87 +/- 0.29; muscle, 4.60 +/- 0.33; prostate, 4.65 +/- 0.48; uterus, 3.87 +/- 0.39; breast, 2.68 +/- 0.11; and blood, 2.35 +/- 0.09.",Pharmacokinetics of [18F]fleroxacin in healthy human subjects studied by using positron emission tomography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257137/),,8.85,238054,DB04576,Fleroxacin
,8257137,plateau concentrations,"The plateau concentrations in tissues (2 to 8 h, in micrograms per gram +/- standard error of the mean) of drug were as follows: brain, 0.83 +/- 0.032; myocardium, 4.53 +/- 0.24; lung, 5.80 +/- 0.48; liver, 7.31 +/- 0.33; spleen, 6.00 +/- 0.47; bowel, 3.53 +/- 0.74; kidney, 8.85 +/- 0.64; bone, 2.87 +/- 0.29; muscle, 4.60 +/- 0.33; prostate, 4.65 +/- 0.48; uterus, 3.87 +/- 0.39; breast, 2.68 +/- 0.11; and blood, 2.35 +/- 0.09.",Pharmacokinetics of [18F]fleroxacin in healthy human subjects studied by using positron emission tomography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257137/),,2.87,238055,DB04576,Fleroxacin
,8257137,plateau concentrations,"The plateau concentrations in tissues (2 to 8 h, in micrograms per gram +/- standard error of the mean) of drug were as follows: brain, 0.83 +/- 0.032; myocardium, 4.53 +/- 0.24; lung, 5.80 +/- 0.48; liver, 7.31 +/- 0.33; spleen, 6.00 +/- 0.47; bowel, 3.53 +/- 0.74; kidney, 8.85 +/- 0.64; bone, 2.87 +/- 0.29; muscle, 4.60 +/- 0.33; prostate, 4.65 +/- 0.48; uterus, 3.87 +/- 0.39; breast, 2.68 +/- 0.11; and blood, 2.35 +/- 0.09.",Pharmacokinetics of [18F]fleroxacin in healthy human subjects studied by using positron emission tomography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257137/),,4.60,238056,DB04576,Fleroxacin
,8257137,plateau concentrations,"The plateau concentrations in tissues (2 to 8 h, in micrograms per gram +/- standard error of the mean) of drug were as follows: brain, 0.83 +/- 0.032; myocardium, 4.53 +/- 0.24; lung, 5.80 +/- 0.48; liver, 7.31 +/- 0.33; spleen, 6.00 +/- 0.47; bowel, 3.53 +/- 0.74; kidney, 8.85 +/- 0.64; bone, 2.87 +/- 0.29; muscle, 4.60 +/- 0.33; prostate, 4.65 +/- 0.48; uterus, 3.87 +/- 0.39; breast, 2.68 +/- 0.11; and blood, 2.35 +/- 0.09.",Pharmacokinetics of [18F]fleroxacin in healthy human subjects studied by using positron emission tomography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257137/),,4.65,238057,DB04576,Fleroxacin
,8257137,plateau concentrations,"The plateau concentrations in tissues (2 to 8 h, in micrograms per gram +/- standard error of the mean) of drug were as follows: brain, 0.83 +/- 0.032; myocardium, 4.53 +/- 0.24; lung, 5.80 +/- 0.48; liver, 7.31 +/- 0.33; spleen, 6.00 +/- 0.47; bowel, 3.53 +/- 0.74; kidney, 8.85 +/- 0.64; bone, 2.87 +/- 0.29; muscle, 4.60 +/- 0.33; prostate, 4.65 +/- 0.48; uterus, 3.87 +/- 0.39; breast, 2.68 +/- 0.11; and blood, 2.35 +/- 0.09.",Pharmacokinetics of [18F]fleroxacin in healthy human subjects studied by using positron emission tomography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257137/),,3.87,238058,DB04576,Fleroxacin
,8257137,plateau concentrations,"The plateau concentrations in tissues (2 to 8 h, in micrograms per gram +/- standard error of the mean) of drug were as follows: brain, 0.83 +/- 0.032; myocardium, 4.53 +/- 0.24; lung, 5.80 +/- 0.48; liver, 7.31 +/- 0.33; spleen, 6.00 +/- 0.47; bowel, 3.53 +/- 0.74; kidney, 8.85 +/- 0.64; bone, 2.87 +/- 0.29; muscle, 4.60 +/- 0.33; prostate, 4.65 +/- 0.48; uterus, 3.87 +/- 0.39; breast, 2.68 +/- 0.11; and blood, 2.35 +/- 0.09.",Pharmacokinetics of [18F]fleroxacin in healthy human subjects studied by using positron emission tomography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257137/),,2.68,238059,DB04576,Fleroxacin
,8257137,plateau concentrations,"The plateau concentrations in tissues (2 to 8 h, in micrograms per gram +/- standard error of the mean) of drug were as follows: brain, 0.83 +/- 0.032; myocardium, 4.53 +/- 0.24; lung, 5.80 +/- 0.48; liver, 7.31 +/- 0.33; spleen, 6.00 +/- 0.47; bowel, 3.53 +/- 0.74; kidney, 8.85 +/- 0.64; bone, 2.87 +/- 0.29; muscle, 4.60 +/- 0.33; prostate, 4.65 +/- 0.48; uterus, 3.87 +/- 0.39; breast, 2.68 +/- 0.11; and blood, 2.35 +/- 0.09.",Pharmacokinetics of [18F]fleroxacin in healthy human subjects studied by using positron emission tomography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257137/),,2.35,238060,DB04576,Fleroxacin
,9755295,plasma elimination half-life (t1/2),"The plasma elimination half-life (t1/2) was estimated as 13.8 +/- 5.5 h for fleroxacin and 7.5 +/- 4.0 h for ciprofloxacin; the maximal plasma concentration (Cmax) was 0.8 +/- 0.3 and 2.3 +/- 1.0 mg/l for fleroxacin and ciprofloxacin, respectively, whilst the volume of distribution (Vd) was 2.5 +/- 1.6 and 0.4 +/- 0.3 liters/kg for fleroxacin and ciprofloxacin, respectively.",Single-dose pharmacokinetic study of ciprofloxacin and fleroxacin in healthy adult Nigerian volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9755295/),h,13.8,239139,DB04576,Fleroxacin
,9755295,plasma elimination half-life (t1/2),"The plasma elimination half-life (t1/2) was estimated as 13.8 +/- 5.5 h for fleroxacin and 7.5 +/- 4.0 h for ciprofloxacin; the maximal plasma concentration (Cmax) was 0.8 +/- 0.3 and 2.3 +/- 1.0 mg/l for fleroxacin and ciprofloxacin, respectively, whilst the volume of distribution (Vd) was 2.5 +/- 1.6 and 0.4 +/- 0.3 liters/kg for fleroxacin and ciprofloxacin, respectively.",Single-dose pharmacokinetic study of ciprofloxacin and fleroxacin in healthy adult Nigerian volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9755295/),h,7.5,239140,DB04576,Fleroxacin
,9755295,maximal plasma concentration (Cmax),"The plasma elimination half-life (t1/2) was estimated as 13.8 +/- 5.5 h for fleroxacin and 7.5 +/- 4.0 h for ciprofloxacin; the maximal plasma concentration (Cmax) was 0.8 +/- 0.3 and 2.3 +/- 1.0 mg/l for fleroxacin and ciprofloxacin, respectively, whilst the volume of distribution (Vd) was 2.5 +/- 1.6 and 0.4 +/- 0.3 liters/kg for fleroxacin and ciprofloxacin, respectively.",Single-dose pharmacokinetic study of ciprofloxacin and fleroxacin in healthy adult Nigerian volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9755295/),[mg] / [l],0.8,239141,DB04576,Fleroxacin
,9755295,maximal plasma concentration (Cmax),"The plasma elimination half-life (t1/2) was estimated as 13.8 +/- 5.5 h for fleroxacin and 7.5 +/- 4.0 h for ciprofloxacin; the maximal plasma concentration (Cmax) was 0.8 +/- 0.3 and 2.3 +/- 1.0 mg/l for fleroxacin and ciprofloxacin, respectively, whilst the volume of distribution (Vd) was 2.5 +/- 1.6 and 0.4 +/- 0.3 liters/kg for fleroxacin and ciprofloxacin, respectively.",Single-dose pharmacokinetic study of ciprofloxacin and fleroxacin in healthy adult Nigerian volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9755295/),[mg] / [l],2.3,239142,DB04576,Fleroxacin
,9755295,volume of distribution (Vd),"The plasma elimination half-life (t1/2) was estimated as 13.8 +/- 5.5 h for fleroxacin and 7.5 +/- 4.0 h for ciprofloxacin; the maximal plasma concentration (Cmax) was 0.8 +/- 0.3 and 2.3 +/- 1.0 mg/l for fleroxacin and ciprofloxacin, respectively, whilst the volume of distribution (Vd) was 2.5 +/- 1.6 and 0.4 +/- 0.3 liters/kg for fleroxacin and ciprofloxacin, respectively.",Single-dose pharmacokinetic study of ciprofloxacin and fleroxacin in healthy adult Nigerian volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9755295/),[l] / [kg],2.5,239143,DB04576,Fleroxacin
,9755295,volume of distribution (Vd),"The plasma elimination half-life (t1/2) was estimated as 13.8 +/- 5.5 h for fleroxacin and 7.5 +/- 4.0 h for ciprofloxacin; the maximal plasma concentration (Cmax) was 0.8 +/- 0.3 and 2.3 +/- 1.0 mg/l for fleroxacin and ciprofloxacin, respectively, whilst the volume of distribution (Vd) was 2.5 +/- 1.6 and 0.4 +/- 0.3 liters/kg for fleroxacin and ciprofloxacin, respectively.",Single-dose pharmacokinetic study of ciprofloxacin and fleroxacin in healthy adult Nigerian volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9755295/),[l] / [kg],0.4,239144,DB04576,Fleroxacin
,3125788,elimination half-life,"Fleroxacin is characterized pharmacokinetically by a long elimination half-life (9 to 10 h) and high concentrations in plasma (e.g., maximum concentration of 2.3 micrograms/ml after an oral dose of 200 mg).","Single- and multiple-dose pharmacokinetics of fleroxacin, a trifluorinated quinolone, in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3125788/),h,9 to 10,242057,DB04576,Fleroxacin
,3125788,maximum concentration,"Fleroxacin is characterized pharmacokinetically by a long elimination half-life (9 to 10 h) and high concentrations in plasma (e.g., maximum concentration of 2.3 micrograms/ml after an oral dose of 200 mg).","Single- and multiple-dose pharmacokinetics of fleroxacin, a trifluorinated quinolone, in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3125788/),[μg] / [ml],2.3,242058,DB04576,Fleroxacin
exceeds,3125788,volume of distribution,The volume of distribution clearly exceeds 1 liter/kg and suggests a good tissue penetration.,"Single- and multiple-dose pharmacokinetics of fleroxacin, a trifluorinated quinolone, in humans. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3125788/),[l] / [kg],1,242059,DB04576,Fleroxacin
,3125788,renal clearance of unbound drug,"The renal clearance of unbound drug was 137 ml/min, and probenecid had no significant effect on renal elimination.","Single- and multiple-dose pharmacokinetics of fleroxacin, a trifluorinated quinolone, in humans. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3125788/),[ml] / [min],137,242060,DB04576,Fleroxacin
,3125788,absolute bioavailability,The absolute bioavailability of the administered tablet was practically 100%.,"Single- and multiple-dose pharmacokinetics of fleroxacin, a trifluorinated quinolone, in humans. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3125788/),%,100,242061,DB04576,Fleroxacin
,1489182,MIC,The fleroxacin MIC required to inhibit 90% of strains tested on buffered charcoal yeast extract agar medium supplemented with 0.1% alpha-ketoglutarate was 0.64 micrograms/ml and was 0.04 microgram/ml when testing was done with buffered yeast extract broth supplemented with 0.1% alpha-ketoglutarate.,"In vitro activities of fleroxacin against clinical isolates of Legionella spp., its pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1489182/),[μg] / [ml],0.64,247453,DB04576,Fleroxacin
,1489182,MIC,The fleroxacin MIC required to inhibit 90% of strains tested on buffered charcoal yeast extract agar medium supplemented with 0.1% alpha-ketoglutarate was 0.64 micrograms/ml and was 0.04 microgram/ml when testing was done with buffered yeast extract broth supplemented with 0.1% alpha-ketoglutarate.,"In vitro activities of fleroxacin against clinical isolates of Legionella spp., its pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1489182/),[μg] / [ml],0.04,247454,DB04576,Fleroxacin
,1489182,peak levels,"Single-dose (10 mg/kg of body weight given intraperitoneally) pharmacokinetic studies performed in guinea pigs with L. pneumophila pneumonia revealed peak levels in plasma and lungs to be 3.3 micrograms/ml and 3.5 micrograms/g, respectively, at 0.5 h and 0.8 microgram/ml and 0.8 microgram/g, respectively, at 1 h.","In vitro activities of fleroxacin against clinical isolates of Legionella spp., its pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1489182/),[μg] / [ml],3.3,247455,DB04576,Fleroxacin
,1489182,peak levels,"Single-dose (10 mg/kg of body weight given intraperitoneally) pharmacokinetic studies performed in guinea pigs with L. pneumophila pneumonia revealed peak levels in plasma and lungs to be 3.3 micrograms/ml and 3.5 micrograms/g, respectively, at 0.5 h and 0.8 microgram/ml and 0.8 microgram/g, respectively, at 1 h.","In vitro activities of fleroxacin against clinical isolates of Legionella spp., its pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1489182/),[μg] / [g],3.5,247456,DB04576,Fleroxacin
,1489182,peak levels,"Single-dose (10 mg/kg of body weight given intraperitoneally) pharmacokinetic studies performed in guinea pigs with L. pneumophila pneumonia revealed peak levels in plasma and lungs to be 3.3 micrograms/ml and 3.5 micrograms/g, respectively, at 0.5 h and 0.8 microgram/ml and 0.8 microgram/g, respectively, at 1 h.","In vitro activities of fleroxacin against clinical isolates of Legionella spp., its pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1489182/),[μg] / [ml],0.8,247457,DB04576,Fleroxacin
,1489182,peak levels,"Single-dose (10 mg/kg of body weight given intraperitoneally) pharmacokinetic studies performed in guinea pigs with L. pneumophila pneumonia revealed peak levels in plasma and lungs to be 3.3 micrograms/ml and 3.5 micrograms/g, respectively, at 0.5 h and 0.8 microgram/ml and 0.8 microgram/g, respectively, at 1 h.","In vitro activities of fleroxacin against clinical isolates of Legionella spp., its pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1489182/),[μg] / [g],0.8,247458,DB04576,Fleroxacin
,1489182,half-life of the terminal phase of elimination,The half-life of the terminal phase of elimination from plasma and lung was approximately 2 h.,"In vitro activities of fleroxacin against clinical isolates of Legionella spp., its pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1489182/),h,2,247459,DB04576,Fleroxacin
,2462556,serum half-life,Fleroxacin is a new fluoroquinolone with a broad antibacterial spectrum and a serum half-life of about 8-12 h.,In-vitro activity of fleroxacin against isolates causing complicated urinary tract infections and concentrations in seminal and prostatic fluid and in prostatic adenoma tissue. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2462556/),h,8-12,250028,DB04576,Fleroxacin
,2462556,mean plasma concentrations,"The mean plasma concentrations of three or four volunteers at each time were 4.2, 3.6 and 1.2 mg/l, respectively.",In-vitro activity of fleroxacin against isolates causing complicated urinary tract infections and concentrations in seminal and prostatic fluid and in prostatic adenoma tissue. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2462556/),[mg] / [l],4.2,250029,DB04576,Fleroxacin
,2462556,mean plasma concentrations,"The mean plasma concentrations of three or four volunteers at each time were 4.2, 3.6 and 1.2 mg/l, respectively.",In-vitro activity of fleroxacin against isolates causing complicated urinary tract infections and concentrations in seminal and prostatic fluid and in prostatic adenoma tissue. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2462556/),[mg] / [l],3.6,250030,DB04576,Fleroxacin
,2462556,mean plasma concentrations,"The mean plasma concentrations of three or four volunteers at each time were 4.2, 3.6 and 1.2 mg/l, respectively.",In-vitro activity of fleroxacin against isolates causing complicated urinary tract infections and concentrations in seminal and prostatic fluid and in prostatic adenoma tissue. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2462556/),[mg] / [l],1.2,250031,DB04576,Fleroxacin
,2462556,prostatic fluid/plasma ratios,"The corresponding prostatic fluid/plasma ratios were 0.30, 0.27 and 1.96, respectively.",In-vitro activity of fleroxacin against isolates causing complicated urinary tract infections and concentrations in seminal and prostatic fluid and in prostatic adenoma tissue. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2462556/),,0.30,250032,DB04576,Fleroxacin
,2462556,prostatic fluid/plasma ratios,"The corresponding prostatic fluid/plasma ratios were 0.30, 0.27 and 1.96, respectively.",In-vitro activity of fleroxacin against isolates causing complicated urinary tract infections and concentrations in seminal and prostatic fluid and in prostatic adenoma tissue. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2462556/),,0.27,250033,DB04576,Fleroxacin
,2462556,prostatic fluid/plasma ratios,"The corresponding prostatic fluid/plasma ratios were 0.30, 0.27 and 1.96, respectively.",In-vitro activity of fleroxacin against isolates causing complicated urinary tract infections and concentrations in seminal and prostatic fluid and in prostatic adenoma tissue. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2462556/),,1.96,250034,DB04576,Fleroxacin
,30076955,formation clearances,The formation clearances of N‑oxide fleroxacin and N‑demethylfleroxacin were 0.520 L/h and 0.496 L/h in patients with CF; these formation clearances were 0.378 L/h and 0.353 L/h in healthy volunteers.,First population pharmacokinetic analysis showing increased quinolone metabolite formation and clearance in patients with cystic fibrosis compared to healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30076955/),[l] / [h],0.520,259050,DB04576,Fleroxacin
,30076955,formation clearances,The formation clearances of N‑oxide fleroxacin and N‑demethylfleroxacin were 0.520 L/h and 0.496 L/h in patients with CF; these formation clearances were 0.378 L/h and 0.353 L/h in healthy volunteers.,First population pharmacokinetic analysis showing increased quinolone metabolite formation and clearance in patients with cystic fibrosis compared to healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30076955/),[l] / [h],0.496,259051,DB04576,Fleroxacin
,30076955,formation clearances,The formation clearances of N‑oxide fleroxacin and N‑demethylfleroxacin were 0.520 L/h and 0.496 L/h in patients with CF; these formation clearances were 0.378 L/h and 0.353 L/h in healthy volunteers.,First population pharmacokinetic analysis showing increased quinolone metabolite formation and clearance in patients with cystic fibrosis compared to healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30076955/),[l] / [h],0.378,259052,DB04576,Fleroxacin
,30076955,formation clearances,The formation clearances of N‑oxide fleroxacin and N‑demethylfleroxacin were 0.520 L/h and 0.496 L/h in patients with CF; these formation clearances were 0.378 L/h and 0.353 L/h in healthy volunteers.,First population pharmacokinetic analysis showing increased quinolone metabolite formation and clearance in patients with cystic fibrosis compared to healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30076955/),[l] / [h],0.353,259053,DB04576,Fleroxacin
,30076955,Renal clearance,Renal clearance in patients with CF divided by that in healthy volunteers was 1.53 for N‑oxide fleroxacin and 1.70 for N‑demethyl fleroxacin.,First population pharmacokinetic analysis showing increased quinolone metabolite formation and clearance in patients with cystic fibrosis compared to healthy volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30076955/),,1.53,259054,DB04576,Fleroxacin
,30076955,Renal clearance,Renal clearance in patients with CF divided by that in healthy volunteers was 1.53 for N‑oxide fleroxacin and 1.70 for N‑demethyl fleroxacin.,First population pharmacokinetic analysis showing increased quinolone metabolite formation and clearance in patients with cystic fibrosis compared to healthy volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30076955/),,1.70,259055,DB04576,Fleroxacin
,17159308,binding constants,The yield binding constants were between 3.19 x 10(4) and 1.21 x 10(5) M(-1).,Interaction between fluoroquinolones and bovine serum albumin studied by affinity capillary electrophoresis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17159308/),1/[M],3.19 x 10(4),263673,DB04576,Fleroxacin
,17159308,binding constants,The yield binding constants were between 3.19 x 10(4) and 1.21 x 10(5) M(-1).,Interaction between fluoroquinolones and bovine serum albumin studied by affinity capillary electrophoresis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17159308/),1/[M],1.21 x 10(5),263674,DB04576,Fleroxacin
,3105446,peak level,"Absorption was rapid, with a mean peak level in serum of 6.1 micrograms/ml, which was attained 0.71 h after administration.","Pharmacokinetics and tissue penetration of Ro 23-6240, a new trifluoroquinolone. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3105446/),[μg] / [ml],6.1,269563,DB04576,Fleroxacin
,3105446,elimination half-life,The elimination half-life in serum was 11.95 h.,"Pharmacokinetics and tissue penetration of Ro 23-6240, a new trifluoroquinolone. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3105446/),h,11.95,269564,DB04576,Fleroxacin
,3105446,percent penetration,The agent penetrated the inflammatory fluid rapidly; the percent penetration was 89.7%.,"Pharmacokinetics and tissue penetration of Ro 23-6240, a new trifluoroquinolone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3105446/),%,89.7,269565,DB04576,Fleroxacin
,3105446,Urinary recovery,Urinary recovery of Ro 23-6240 was 58.6% by 72 h.,"Pharmacokinetics and tissue penetration of Ro 23-6240, a new trifluoroquinolone. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3105446/),%,58.6,269566,DB04576,Fleroxacin
,3144532,peak serum concentrations,"The peak serum concentrations of unchanged fleroxacin were about 1.5, 3 and 5 mg/l at 1-2 h after single oral doses of 100, 200 and 400 mg, respectively.",Clinical pharmacokinetics and tolerance of fleroxacin in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3144532/),[mg] / [l],1.5,269953,DB04576,Fleroxacin
,3144532,peak serum concentrations,"The peak serum concentrations of unchanged fleroxacin were about 1.5, 3 and 5 mg/l at 1-2 h after single oral doses of 100, 200 and 400 mg, respectively.",Clinical pharmacokinetics and tolerance of fleroxacin in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3144532/),[mg] / [l],3,269954,DB04576,Fleroxacin
,3144532,peak serum concentrations,"The peak serum concentrations of unchanged fleroxacin were about 1.5, 3 and 5 mg/l at 1-2 h after single oral doses of 100, 200 and 400 mg, respectively.",Clinical pharmacokinetics and tolerance of fleroxacin in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3144532/),[mg] / [l],5,269955,DB04576,Fleroxacin
,3144532,apparent serum elimination half-life,"The apparent serum elimination half-life was about 10 h, independent of the dose.",Clinical pharmacokinetics and tolerance of fleroxacin in healthy male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3144532/),h,10,269956,DB04576,Fleroxacin
,3144532,Steady state serum concentrations,"Steady state serum concentrations were achieved from day 3 onwards by repeated doses of twice-a-day dosage regimen and were 2-4 and 5-9 mg/l after 200 and 400 mg bid, respectively.",Clinical pharmacokinetics and tolerance of fleroxacin in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3144532/),[mg] / [l],2-4,269957,DB04576,Fleroxacin
,3144532,Steady state serum concentrations,"Steady state serum concentrations were achieved from day 3 onwards by repeated doses of twice-a-day dosage regimen and were 2-4 and 5-9 mg/l after 200 and 400 mg bid, respectively.",Clinical pharmacokinetics and tolerance of fleroxacin in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3144532/),[mg] / [l],5-9,269958,DB04576,Fleroxacin
,3144532,concentrations,The mean concentrations of unchanged drug in urine were about 200 and 300 mg/l at the respective dosages.,Clinical pharmacokinetics and tolerance of fleroxacin in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3144532/),,300,269959,DB04576,Fleroxacin
,3144532,serum protein binding,The serum protein binding of fleroxacin was 32%.,Clinical pharmacokinetics and tolerance of fleroxacin in healthy male volunteers. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3144532/),%,32,269960,DB04576,Fleroxacin
